SYMPOSIUM:MOLECULARGENETICSINSARCOMAOsteosarcomaDevelopmentandStemCellDifferentiationNiTangMD,PhD,Wen-XinSongMD,JinyongLuoMD,RexC.HaydonMD,PhD,Tong-ChuanHeMD,PhDPublishedonline:18June2008ÓTheAssociationofBoneandJointSurgeons2008AbstractOsteosarcomaisthemostcommonnonhema-tologicmalignancyofboneinchildrenandadults.Thepeakincidenceoccursintheseconddecadeoflife,withasmallerpeakafterage50.Osteosarcomatypicallyarisesaroundthegrowthplateoflongbones.Mostosteosarcomatumorsareofhighgradeandtendtodeveloppulmonarymetastases.Despiteclinicalimprovements,patientswithmetastaticorrecurrentdiseaseshaveapoorprognosis.Here,wereviewedthecurrentunderstandingofhumanosteosarcoma,withanemphasisonpotentiallinksbetweendefectiveosteogenicdifferentiationandbonetumorigene-sis.Existingdataindicateosteosarcomatumorsdisplayabroadrangeofgeneticandmolecularalterations,includingthegains,losses,orarrangementsofchromosomalregions,inactivationoftumorsuppressorgenes,andthederegula-tionofmajorsignalingpathways.However,exceptforp53and/orRBmutations,mostalterationsarenotconstantlydetectedinthemajorityofosteosarcomatumors.Witharapidexpansionofourknowledgeaboutstemcellbiology,emergingevidencesuggestsosteosarcomashouldberegardedasadifferentiationdiseasecausedbygeneticandepigeneticchangesthatinterruptosteoblastdifferentiationfrommesenchymalstemcells.Understandingthemolec-ularpathogenesisofhumanosteosarcomacouldultimatelyleadtothedevelopmentofdiagnosticandprognosticmarkers,aswellastargetedtherapeuticsforosteosarcomapatients.IntroductionOsteosarcoma(OS)isthemostfrequentprimarybonesarcoma,comprisingapproximately20%ofallbonetumorsandabout5%ofpediatrictumorsoverall[34,67,73,75,77,94,127,136,146,210,252,259].Infact,OSistheﬁfthmostcommonmalignancyamongindividualsaged15to19years,andthesecondmostcommoninadoles-cenceafterlymphoma.OShasabimodalagedistribution,withtheﬁrstpeakintheseconddecadeoflifeandasecondpeakinelderlyadults[146,210].HigherincidencesinboysandinAfrican-Americanchildrenhavebeenreported[146,210].Themostcommonlocationsinyoungadultsareareaswithrapidbonegrowth,includingdistalfemur,proximaltibia,andproximalhumerus.Nevertheless,OSisrelativelyrare,andlessthan1000newcasesarediagnosedeachyearintheUnitedStates,accountingforlessthan2%ofallnewcancercasesintheU.S.[146,210].AlthoughOSdevelopmentisassociatedwithseveralgeneticpredispositionconditions,mostOStumorsaresporadicwithoutfamilialpatterns[67,73,77,94,146,210,252,259].OurcurrentunderstandingofOSetiologyisratherlimited.Exposuretochemicalberylliumoxide[51],orthopaedicprostheses[101],andtheFBJvirus[51]causesOSinanimalmodels,buttheirroleinhumanOSisunknown.SV40viralDNAhasbeendetectedinupto50%ofOStumors[24,125,161],whileitisunclearwhetherOneormoreoftheauthorshavereceivedfundingfromtheAmericanCancerSociety(TCH),TheBrinsonFoundation(RCH,TCH),theOrthopaedicResearchandEducationFoundation(RCH),andtheNationalInstitutesofHealth(RCH,TCH).N.Tang,J.Luo,T.-C.HeTheSecondAfﬁliatedHospitalandtheKeyLaboratoryofDiagnosticMedicinedesignatedbyChineseMinistryofEducation,ChongqingMedicalUniversity,Chongqing,ChinaN.Tang,W.-X.Song,J.Luo,R.C.Haydon,T.-C.He(&)MolecularOncologyLaboratory,DepartmentofSurgery,TheUniversityofChicagoMedicalCenter,5841SouthMarylandAvenue,MC3079,Chicago,IL60637,USAe-mail:tche@surgery.bsd.uchicago.edu123ClinOrthopRelatRes(2008)466:2114–2130DOI10.1007/s11999-008-0335-zSV40playsanyroleinOStumorigenesis[51,62].Radi-ationexposureisawell-documentedriskfactorforOS[51,88,147,239,256],buttheintervalbetweenradiationexposureandtumorappearanceislong,andhenceitislikelyirrelevanttothedevelopmentofmostconventionalOStumors.Nevertheless,radiationcouldberesponsibleforthedevelopmentofsecondaryOSpostradiationtherapyofcertainprimarytumors.DespitetherelativelowincidenceofOS,morethan20,000articlesdescribingthepathogenicandclinicalaspectsofOShavebeenpublishedthusfar.Assummarizedinthissurvey,OSdisplaysabroadrangeofgeneticandepigeneticalterations,andyetnoconsensuschangeshavebeenidentiﬁedinallOStumors[34,67,73,75,77,94,127,136,146,210,252,259].Withtherapidexpansionofourknowledgeaboutstemcellbiologyandcancerstemcells[204,217,260,278],increasingevidencesuggestsOSmaybeconsideredadifferentiationdisease[75,231].Terminaldifferentiationofosteoblasts,whicharederivedfrommultipotentmesenchymalstemcells,isawell-orchestratedprocessandcontrolledbyacascadeofregu-latorysignaling[36,38,39,75,82,96,114,129,136,171,173,187,270].PathologicandmolecularfeaturesofmostifnotallOStumorsstronglysuggestOSmaybecausedbygeneticandepigeneticdisruptionsofosteoblastdifferenti-ationpathway[75,231].Promotingdifferentiationand/orcircumventingdifferentiationdefectsmaybeexploitedasanefﬁcaciousadjuvanttherapyforOSsincecurrentchemotherapiesmostlytargettheproliferativeaspectsofOStumors[75,76,188].Inthissurvey,webrieﬂyreviewcurrentlyidentiﬁedgeneticalterationsthatmaybeassociatedwithosteosar-comapathogenesis,andthenfocusonrecentﬁndingsthatsuggestpotentiallinksbetweendefectiveosteogenicdif-ferentiationofmesenchymalstemcellsandosteosarcomadevelopment.Webelievethislineofinvestigationwillprovideinsightintothepathogenesisofosteosarcoma.SearchStrategiesandCriteriaWeperformedPubMedsearchesoftheliteraturerelevanttothesubjectwiththefollowingkeywordsutilizedindividu-allyorincombination:osteosarcoma(20,168references),osteosarcomapathogenesis(8232references),osteosar-comagenetics(3587references),osteosarcomamutation(1232references),osteosarcomabiology(238references),osteosarcomastemcell(669references),osteosarcomastemcelldifferentiation(99references),andosteosarcomalungmetastasis(894references),asofMarch2008.Publi-cationsinlanguagesotherthanEnglish,pertinentreviewarticles,andbookchapterswerenotexcludedinoursear-ches.However,wemostlyreviewedtheEnglishabstractsofthearticlespublishedinotherlanguagesandonlyutilizedthearticlesthataddedanyinformationtothisreview.Wheneverinformationoverlapped,wereferencedthemostrecentarticlesbuiltonconclusionsorreportsofpreviousarticles.OursearchesofarticlespublishedintheEnglishlanguagerevealedconsiderableoverlapinarticlesidentiﬁedunderthedifferentsearchterms,andwecarefullyreviewedthearticlesforpertinencetoourreviewarticle.Inthisreview,weprimarilyfocusedonrelevantpublicationswithinthepast10years,whilenotexcludingolderbutcommonlyreferencedandhighlyregardedpriorpublica-tions.Wesuspectmanyoftheosteosarcomacasesdescribedintheliteraturerepresenthigh-gradeosteosarcomas.ClinicalAspectsofHumanOSMostOSpatientspresentwithpainandswellingintheaffectedregionsaftertraumaorvigorousphysicalactivities[146].ThediagnosisofOSisusuallymadebyradiographicappearanceandlocationoftumorlesionsandabiopsyforpathologicconﬁrmation[146].OScanpresentradio-graphicallyasalytic,sclerotic,ormixedlytic-scleroticlesion[146].Upto20%ofOSpatientspresentwithradiographicallydetectablelungmetastases,whereas80%ofpatientswithlocalizedOSdevelopmetastasesaftersurgicalresectionalone[146].DeathfromOSisusuallytheresultofprogressivepulmonarymetastasiswithrespi-ratoryfailure[146].OShasabroadspectrumofhistologicappearanceswithcommoncharacteristicscontaininghighlyproliferativemalignantmesenchymalstemcellsandtheproductionofosteoidand/orbonebytumorcells[62,146].Histologically,OScanbedividedintoseveralsubtypes.ConventionalosteoblasticOSmakesupabout70%,whereaschondrob-lasticandﬁbroblasticOStumorsarethenextmostcommonat10%each[62,73,102,231].OtherOStypesincludeanaplastic,telangiectatic,giantcell-rich,andsmallcellOS[102].ConventionalOSisaprimaryintramedullaryhigh-gradesarcoma.CurrentclinicalmanagementofOSincludespre-andpostoperativechemotherapyandsurgicalresection[62].Onlyabout20%ofOSpatientscanbecuredwithoutchemotherapy[62,102,146].Chemotherapyagentsincludedoxorubicin,cisplatin,ifosfamide,andmethotrexate[62,102,127,146].Surgicalremovaloftheprimarytumorrequiresawide-marginresection,followedbylimbsalvagereconstruction[62,102,127,146].OSprognosticindicatorsincludeextentofdiseaseatdiagnosis,sizeandlocationofthetumor,responsetochemotherapy,andsurgicalremission[62,102,127,146].ForthoseOSpatientswhopresentwithoutdetectablemetastases,approximately70%ofthemcanachievelong-termsurvival[62,102,127,146].Theremaining30%willVolume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2115123relapse,mostlywithin5years[62,102,127,146].Pul-monarymetastasisisthemostcommonformofdistantspread.Theaveragesurvivalafterarecurrenceislessthan1year[62,102,127,146].Removalofasurgicallyresectablerecurrenceorpulmonarymetastasisimprovessurvival[62,102,127,146].Thus,amajorchallengeinclinicalmanagementofOSistoidentifypoorresponderstochemotherapyand/ortodetectearlymetastaticlesions.ChromosomalAbnormalitiesinHumanOSUnlikeothersarcomas,suchassynovialsarcoma,alveolarrhabdomyosarcoma,andEwing’ssarcoma,nospeciﬁctranslocationsorgeneticabnormalitieshavebeenidentiﬁedinOS[34,67,73,75,77,94,127,136,146,210,252,259].Nevertheless,nearly70%ofOStumorsdisplayamultitudeofcytogeneticabnormalities[146,210].Theploidynum-berinOShasrangedfromhaploidytonear-hexaploidy.Chromosomalregionsof1p11–p13,1q11–q12,1q21–q22,11p14–p15,14p11–p13,15p11–p13,17p,and19q13aremostcommonlyinvolvedinstructuralabnormalities[146,210].Gainofchromosome1andlossofchromosomes9,10,13,and17aremostcommonoverall.Lessfrequentlyinvolvedchromosomalregionswere13q14(locusofRB1),12p12–pter(locusofKRAS),6q11–q4,and8p23[146,210].Acombinationofseveraldetectionmodalitieshaspro-videdamoreaccurateassessmentofthecomplexcytogeneticaberrationsinOS[146,210].Themostfre-quentlydetectedampliﬁcationsincludechromosomalregions6p12–p21(28%),17p11.2(32%),and12q13–q14(8%)[210].Severalotherrecurrentchromosomallosses(2q,3p,9,10p,12q,13q,14q,15q,16,17p,and18q)andchromosomalgains(Xp,Xq,5q,6p,8q,17p,and20q)werealsoidentiﬁed,aswellasseveralrecurrentbreakpointclustersandnonrecurrentreciprocaltranslocations[210].TheseﬁndingsfurtherhighlightthecomplexityandtheinstabilityofthegeneticmakeupofOStumors.GeneticAlterationsofTumorSuppressionGenesinHumanOSRetinoblastomaTumorSuppressorIndividualsaffectedbyhereditaryretinoblastoma(RB)heterozygousforagermlineinactivationofRB1haveanapproximately1000timeshigherincidenceofOS.RB1mapsto13q14[1,111].GeneticalterationsofRB1havebeenfoundinupto70%ofsporadicOScases[2,4,12,13,164,215,235,248,267].Lossofheterozygosity(LOH)ofRB1locusispresentin60%to70%ofOStumors[12,48,271],whereasstructuralrearrangementsandpointmuta-tionsoccurlesscommonly(30%and10%,respectively)[2,4,12,13,164,215,235,248,267].Furthermore,LOHattheRB1locushasbeenproposedasapoorprognosticfactorinOS[146,210].RBisanimportantregulatorofG1/Scellcyclepro-gression[178].DuringG1/Stransition,RBbecomesphosphorylated,resultingintheactivationofE2FfactorsthatbindtothedephosphorylatedRBproteinandpromoteDNAsynthesisandG1toStransition[178].CDK4incomplexwithcyclinD1phosphorylatesRB.Thus,ampli-ﬁcationoroverexpressionofthesegenesresultsinfunctionalinactivationoftheRBpathway.TheCDKsareregulatedbyaseriesofinhibitoryproteins,includingp16INK4a,asanegativeregulatorofcellcycleprogression(seebelow).Lossofp16INK4aexpressionoccursinosteo-genicsarcomaslackingRB1alterations[179].p53TumorSuppressorThetumorsuppressorgeneTP53islocatedat17p13,aregionfrequentlyidentiﬁedasabnormalinOS[29,210].TP53encodesatranscriptionfactorandregulatesgenesinvolvedincellcycle,DNAdamageresponse,andapop-tosis[40,69,87,126].AlterationsinTP53observedinOStumorsconsistedofpointmutations(20%–30%,mostlymissensemutations),grossgenerearrangements(10%–20%),andallelicloss(75%–80%)[3,20,28,119,152,162,163,169,170,184,186,199,206,214,221,227,236,237,241,249,271].TheassociationofTP53withOSisfurthersupportedbythehighriskofOSinpatientswiththeLi-Fraumenisyndrome,anautosomaldominantdisordercharacterizedbyagermlinemutationofTP53[128,144,145,194,223].GermlinemutationsofTP53havebeenidentiﬁedinasmallpercentage(3%)ofsporadicOScases[112,156,236,237].However,TP53mutationstatusisseeminglynotassociatedwiththestagesofOStumorand/ormetastasis[60].Nevertheless,themutationstatusofTP53,andtoalesserextentofRB1,couldserveasavaluableindicatorforpredictingchemoresistanceofOS[64].p16INK4aandp14ARFCDKInhibitorsINK4A(alsoknownasCDKN2A),localizedto9p21,encodesp16INK4a,atumorsuppressorthatfunctionsinpartthroughtheinhibitionofCDK4(seebelow)[198].Thep16INK4aproteincanimposeasustainedG1arrest[123,198].In87OSspecimensfrom79patients,INK4Achangeswereobservedinﬁveof55casesexamined(fourdeletionsandonerearrangement),whereasnoINK4Aexon2-pointmutationsormethylationweredetected[94,140,2116Tangetal.ClinicalOrthopaedicsandRelatedResearch123162,210,257].CDK4geneampliﬁcationoccurredinsixof67tumors,butnoneofthosewithINK4Aalterations[94,210].Theabsenceofexpressionofp16INK4acorrelatedwithdecreasedsurvivalinpediatricOSpatients[94,210].INK4Aalsoencodesp14ARFthroughbicistronictran-scriptioninvolvingtheuseofanalternativereadingframe[198].Thep14proteinisstructurallyandfunctionallyunrelatedtop16INK4a[66,123].Whereasp16INK4aindi-rectlyregulatesRB1function,p14regulatesTP53functionbybindingMDM2(seebelow)andsequesteringitinthenucleolus,therebypreventingitfromshuttlingp53tothecytoplasmfordegradation[192,279].INK4Aisdeletedinapproximately10%ofOS,andalmostalldeletionswouldbeexpectedtoknockoutexpressionofp14ARFaswell[133].Becauselossofp14ARFshouldreleaseMDM2fromthisnegativeregulatorymechanism,deletionofINK4ArepresentsanothermechanismoffunctionalTP53inacti-vation.AsthealternativeproductsofINK4A,p14ARFandp16INK4a,interactnegativelywithMDM2andCDK4,deletionsoftheINK4Agenewouldbefunctionallyequivalentto12q13ampliﬁcationofbothMDM2andCDK4[94,146,210,252].Asaresult,eitheroftwosin-gulargeneticevents(ie,INK4Adeletionor12q13ampliﬁcation)caninactivatetwoseparatecriticalpathwaysofcellcyclecontrol[94,146,210,252].ActivationofOncogenesinHumanOSThec-MYCproductisinvolvedinregulatingcellgrowthandDNAreplication[32,177].Sevento12percentofOStumorshaveMYCampliﬁcation[9,10,120,193].ThisgeneticalterationmaybemorecommoninPageticOS(seebelow)[210].Attheexpressionlevel,MYCexpressioninOSwaselevatedinnineof21(42%)patientswhorelapsedandinfourof17(23%)patientswhoremaineddisease-free[53].FOSformsheterodimerictranscriptioncomplexeswithspeciﬁcJUNproteinsthatregulatetargetgenesinvolvedincellgrowth,differentiation,transformation,andbonemetabolism[208,255].Whentheviralhomologv-FOSisinjectedintorodents,OSformationisinduced[208,255].TransgenicmiceoverexpressingFOSinbonedevelopOS[208,255].Inonereport[266],61%ofOStumorsexpressedhighlevelsofFOS.ThehighestlevelsofFOS(andofJUN)expressionhavebeenreportedinconven-tionalOS[50].FOSwasexpressedinnineof21(42%)patientswhosubsequentlydevelopedmetastases[50,53,193].Further,FOSwasmorefrequentlyexpressedinhigh-gradethaninlow-gradelesions[210].MDM2,locatedat12q13,encodesaproteinthatnega-tivelymodulatesTP53functionbybindingthep53proteinandphysicallyblockingtheregionofp53responsiblefortranscriptionalactivationofspeciﬁcgenesandtargetsp53fordegradation[29,69,87,126,247].AmpliﬁcationleadingtoMDM2overexpressionfunctionallysuppressesp53eveninthepresenceofwild-typep53protein[30,124,184,185].The12q13region,containingMDM2andCDK4,isampliﬁedin5%to10%ofOS[132,167,184,185].How-ever,someampliconsinthisregion(12q13–q14)donotincludeMDM2[49].AlthoughMDM2ampliﬁcationhasbeenrelatedtoprogressionandmetastasesinOS[119,174],MDM2ampliﬁcationandTP53mutationshavenotcorre-latedwithresponsetochemotherapyorsurvival[274].AlthoughCDK4geneampliﬁcationhasbeendetectedinalowpercentageofOScases[93,141],CDK4proteinsarehighlyexpressedin65%oflow-gradeOS[200].CDK4formsacomplexwithcyclinD1andphosphorylatesRB,thusreleasingtheE2Ftranscriptionfactorfromitsinter-actionwithRB[33,179].IthasbeensuggestedhigherCDK4levelssecondarytoampliﬁcationmaystoichiomet-ricallyfavorRBphosphorylation,therebyimpairingcellcyclecontrol[43,107,140,213].HighlevelsofCDK4mayalsodrive12q13–q15ampliﬁcationindependentlyofMDM2becausediscontinuityofthe12q13ampliconshasbeenidentiﬁed[15,43,93,257].HighlevelsofcyclinD1(CCND1)havebeendetectedin22%ofOS,andCCND1ampliﬁcationhasbeenreportedin4%ofOS[140,257].Furthermore,theabsenceofcyclinD1expressionisapowerfulprognosticfactorbecauseitisassociatedwithametastaticphenotype[166].ERBB2(alsoknownasHER2/neuandc-erbB-2)encodesaproteinstructurallyhomologoustotheEGFreceptorwithoutaknownligand.Atthetimeofinitialbiopsy,20of47OS(42.6%)displayedhighlevelsofERBB2expression,relativetoadjacentnormaltissues[63].However,theactualroleofERBB2expressioninOSdevelopmentremainsunclear.Onestudy[281]found,inpatientswithhigh-gradeOSwithoutmetastaticdiseaseatpresentation,increasedexpressionofERBB2intumorcellswasassociatedwithanincreasedprobabilityofevent-freeandoverallsurvival[281],whileotherstudiesdemon-stratedcytoplasmicstainingofERBB2inpretreatmentOScorrelatedwithanincreasedriskofpulmonarymetastasesandOScellspositiveforERBB2mayrepresentachemoresistantaggressivesubpopulationofOS[281].DeregulationofMajorSignalingPathwaysinHumanOSWntsareafamilyofhighlyconserved,secretedproteinsthatplayanimportantroleindevelopmentandtumori-genesis[8,22,56,58,61,110,131,134,176,182,183,197,203,246,262,264].ManyWntsandtheirreceptorsareexpressedinearlyboneprogenitors[58,61,110,134,Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2117123183].AberrantactivationofWntsignalingisassociatedwithmanycommonhumancancers[8,56,134,137,203,246].Elevatedcytoplasmicand/ornuclearlocalizationofb-catenin,acriticalmediatorofthecanonicalWntpath-way,hasbeendetectedinthemajorityofOStumorsandmaycorrelatewithOSmetastasis[74,90].Sporadicmutationsofb-cateninhavealsobeenidentiﬁed[89].OSexpressinghighlevelsofWntcoreceptorLRP5islessdifferentiatedandisassociatedwithdecreasedpatientsurvival[80].Inaddition,ectopicexpressionoftheWntagonistDKK3suppressedinvasionandmotilityofOSlineSAOS2[81].TGFb/BMPfamilymembersplayimportantrolesinregulatingcellgrowthanddevelopment[135,149–151,282].InOStumors,expressionofTGFb1andTGFb3ishigherthanthatofTGFb2[113].TGFb3expressionstronglyrelatedtodiseaseprogression[113].Also,althoughincreasedexpressionofTGFb2andb3andVEGFwascorrelatedwithOSgrade,onlyVEGFexpressionwascorrelatedwithsurvival[92].BMPsandtheirreceptors(BMPRs)regulateboneandskeletaldevelopment[135,282].MutationsinBMPsorBMPRsleadtoskeletaldefects,familialprimarypulmonaryhypertension,andneoplasias[280].NumerousBMPsand/orBMPRsarehighlyexpressedinOStumors[91,143,258].Overex-pressionoftheBMPR-IImayberelatedtopoorprognosisinmalignantandmetastaticOStumors[59,275].METencodesthereceptorforhepatocytegrowthfactor(HGF/scatterfactor),acytokinethatstimulatescellpro-liferationandmotility[46,172,207,216].MET/HGFisthereforebelievedtoplayaroleinstromal-epithelialinteraction.Approximately60%ofOStumorsexpressedMETreceptorathighlevels[46,216],whilesomeOSsamplesdemonstratedbothHGFandMETexpression[46].Thus,theactivationofMET/HGFpathwaymaycontributetotheaggressivebehaviorofOStumors[14,21,46,207].GLI,originallyidentiﬁedasanoncogeneampliﬁedinmalignantglioma,playsaroleintransducingthesonichedgehog(Shh)signal[168].Shhisinvolvedinanterior-posteriorpatterningofthelimbs,andalterationsinGLI1expressionmayplayaroleinOSdevelopment[94].GLI1islocatedat12q13.3–q14.1andisazincﬁngertranscrip-tionfactor.GLIwascoampliﬁedwithCDK4intwoofsixOSsamples[257].AnincreasedexpressionofGLIwasdetectedinmanysarcomasincludingsevenofeightOStumors,especiallyinundifferentiatedtumors[205,224].FGFR2playsanimportantroleinboneandskeletaldevelopment,andinheritedmutationsofFGFR2underlieskeletaldysplasias[261].LOHofFGFR2at10q26hasbeendetectedinhigh-gradeOS,whilemutationswerenotfoundinFGFR2[160].IGFsareproducedbyosteoblastsandactthroughtheirreceptorstoactivateproliferationanddifferentiation.OScellsoverexpressIGF1R.Additionalinvestigationsareneededtodeterminewhetherthesepath-wayscontributetothemalignantphenotypeofOS[139].OtherGeneticand/orMolecularChangesinHumanOSPagetDiseaseofBonePagetdiseaseofboneisaheritablebonedisordercharac-terizedbyrapidboneremodelingleadingtoabnormalboneformation.Approximately1%ofpatientswithPagetdis-easeofbonedevelopOS[157].PatientswithPagetdiseaseofboneaccountforasubstantialfractionofOSoccurringaftertheageof60years.GeneticlinkageofPagetdiseasehasbeendemonstratedtoinvolve18q21.1–q22[86,269].OfinterestisthedemonstrationofapossibleroleoftheFOSgeneinthepathogenesisofPagetdisease[11],aswellasRANK(alsoknownasTNFRSF11A)andOPG(alsoknownasTNFRSF11B)[68,157,222],althoughthebonaﬁdePagetdiseasegene(s)remaintobeidentiﬁed.MutationsofRECQHelicasesRECQhelicasesareconservedproteinsthatshareahighlyhomologousDNAhelicasedomain,andmutationsinthreeoftheﬁveRECQhelicasesareassociatedwithcancerpredispositionsyndromes,namelyRothmund-Thomsonsyndrome,Bloomsyndrome,andWernersyndrome[252].Rothmund-ThomsonsyndromeisanautosomalrecessivedisorderwithanincreasedriskforOS.Inonecohortof41patientswithRothmund-Thomsonsyndrome,13(32%)developedOS,tendingtodevelopatayoungerage(medianage,9years)[254].ThepresenceofRECQL4mutationsiscorrelatedwiththeriskfordevelopingOS[253].BloomsyndromeandWernersyndromehavesomeoverlappingclinicalfeatures,andbothexhibitpredisposi-tionstodevelopingcancers[78].PatientswithBloomsyndromehavemutationsintheBLMgeneandarepre-disposedtoallthetypesofcancersatamuchyoungerageandatahigherfrequency[54].PatientswithWernersyn-dromehavemutationsintheWRNgeneandarepredisposedtodevelopingOSandothertumors[65].OfthethreeOSpredispositionsyndromes,Rothmund-Thom-sonsyndromeappearstohavethehighestandmostspeciﬁcriskforOStumor[252].Thus,inactivationofthehelicasepathwaysmaycontributetoOSdevelopment.TelomeraseandTelomeresinOSTelomerase(TERT)activityisundetectableinnormalcells,benignlesions,andlow-gradesarcomas[272]andis2118Tangetal.ClinicalOrthopaedicsandRelatedResearch123presentinonlyaportionofOS[5,212,242].TERTactivityinOStumorsexhibitedaninversecorrelationwithoccurrenceofpulmonarymetastasesinpatientstreatedwithchemotherapy[211].Alternativelengtheningoftelo-meresinOSmaybeequivalenttoTERTactivity[5].Of62OSpatients,asubsetofcaseslackedbothTERTactivityandevidenceofalternativelengtheningoftelomeres,whichwasassociatedwithafavorableprognosis[242].ActivationofMatrixMetalloproteinases(MMPs)MMPsarezinc-dependentendopeptidasesthatdegradeextracellularmatrixproteins.MMPsarecontrolledbybothproenzymesandinhibitionoftissueinhibitorofMMPs(TIMPs).MMP2andMMP9wereoverexpressedinOScellsandassociatedwiththeabilityofthecellstometas-tasize[18].Increasedexpressionofmembrane-typeMMP1hasbeencorrelatedwithpoorprognosisinOSpatients[240].UpregulationofTIMP1isassociatedwithpoorclinicaloutcomeforOS.BindingofTIMP-1toanunknownreceptorsystemreportedlytriggersRas/Raf1/FAKsignalinginOS.Thus,TIMP1mayhaveadualeffectontumorprogression[47,84].Neuroﬁbromatosis-2(NF2)/MerlinNF2encodesMerlin,anezrin-radixin-moesin(ERM)-relatedproteinthatfunctionsasatumorsuppressor[153,154].NF2nullmicedieinearlyembryogenesis,whereasNF2heterozygousmiceareviablebutdevelopavarietyofhighlymetastatictumors,includingOSandhepatocellularcarcinoma,withlonglatencies[155].Merlinmediatescontactinhibitionofgrowththroughsignalsfromtheextracellularmatrix.Athighcelldensity,Merlinbecomeshypophosphorylatedandinhibitscellgrowthinresponsetohyaluronatethroughspeciﬁcinteractionwiththecyto-plasmictailofCD44[55,109,118,218].Well-dedifferentiatedOStumorshaveahigherlevelofCD44[94].Merlinmaycontrolthestabilityoftheadherensjunctionbyitsinteractionwiththeactincytoskeleton.Lossofthisfunctionmayleadtotumorigenesisandmetastasis[106,121].TheN-terminalregionofMerlinincreasesp53stabilitybyinhibitingtheMDM2-mediatedp53degrada-tion.Thus,lossofMerlinmayalsodestabilizep53[108].AdditionalGeneticChangesThebuddinguninhibitedbybenzimidazole3(BUB3)wasidentiﬁedinaregionofLOHat10q26in20high-gradeOStumors,althoughnomutationsofBUB3wereobservedinOS.BUB3playsaroleinchromosomehomeostasisandisacomponentofthespindleassemblycheckpointcomplex[23],alterationsofwhichcouldunderlietheaneuploidythatischaracteristicofOS[160].Interestingly,BUB3isatargetofE2F[6].Primasepolypeptide1(PRIM1),locatedat12q13,isampliﬁedinnineof22OStumors[276].MDM2andCDK4areconsideredthemostimportantampliﬁcationtargetsin12q13–q15[202],buttheregionalsocontainsnumerousgenes,includingCHOP(ie,DDIT3),SAS(sarcomaampliﬁedsequence)[159],OS-4[226],OS-9[225],PRIM1[276],andotherasyetpoorlycharacterizedgenes[44].AmpliﬁcationofSASwasreportedin36%ofOS[180]andwaslinkedwithincreasedCDK4expression[268].OthersuspectedoncogenesincludeMAPK7andperipheralmyelinprotein(PMP22/GAS3),bothlocatedat17p11.2.MAPK7wasampliﬁedin10of19OSsamples[243].FrequentampliﬁcationofPMP22isobservedinhigh-gradeOS[244].HMGICgene(alsoknownasHMGA2,localizedto12q14–q15)wasrearrangedbyfusingwiththekeratinsulfateproteoglycanlumicangeneLUMinanOSline[115].HMGICgenewasalsoampliﬁedandrearrangedintwoprimaryOS[16].Alleliclossat4q32–q34wasidentiﬁedin63%ofOS[220].Highfrequenciesofalleliclosshavebeendetectedat3q26[79,117],13q,17p,and18q,suggestingothertumorsuppressorgenesmayexistat3qand18q[271].ExpressionofDCC(deletedincoloncancer),locatedon18q21,decreasesinOS[85].TwopotentialOSsuppressorgenelociweredemonstratedat6q14(imbalancein77%ofcases)and15q21(58%ofcases)[175].Genome-wideApproachestoIdentiﬁcationsofOS-associatedGenesMicroarray-basedexpressionproﬁlinganalysishasbecomeanincreasinglycommonpracticetoidentifygenesassoci-atedwithOSpathogenesis[103].Onesuchstudyhasshown,amongthe100mostup-anddownregulatedgenes,35areaffectedinallthreeOSlines,witheightgenesshowinganincreaseand27genesareductionintheexpressionlevelcomparedwithnormalhumanosteoblasts[265].Theseﬁndingshaveprovidedaproof-of-principleofgenome-wideapproachestounravelingthepathogenesisofOS.OSMetastasis-associatedGenesEzrin,amemberoftheERMproteins,hasbeenidentiﬁedasametastasis-relatedgenethatisdifferentiallyexpressedinmurineOSlineswithdifferentialmetastaticpotential[104–106].Ezrinisinvolvedinintracellularsignaltrans-ductionregulatingcellmigrationandmetastasis[251]andVolume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2119123isexpressedinavarietyofcancers,someofwhichareassociatedwithpooroutcome[142,148].Inastudyof19patientswithOS,thedisease-freeintervalofOSpatientswithhighezrinexpressionwassubstantiallyshorterthanthatinpatientswithlowezrinexpression,andtheriskofmetastaticrelapsewas80%greaterintheformergroup[106].ExpressionofS100A6wasreportedin84%ofanalyzedOSspecimens[138].ThereisatrendtowarddecreasedclinicallyevidentmetastasiswithincreasedS100A6staining.OverexpressionofS100A6inOScellsdecreasescellmotilityandanchorage-independentgrowth[138].Theseﬁndingssuggest,whileS100A6iscommonlyover-expressedinOS,lossofitsexpressionmaycorrelatewithametastaticphenotype.Aclusterof16typesofS100genesislocatedon1q21,whichisfrequentlyampliﬁedorrear-ranged[25,35,37,71,158,190,209].S100proteinsconstituteagroupofnearly20proteinsthatcontainwell-conservedEF-handcalcium-bindingdomains[209].Sev-eralS100proteinshavebeenassociatedwithhumancancers[25,35,37,71,158,190,209].Annexin2(AnxA2)wasdownregulatedinmetastaticsamples[57].AnxA2belongstoalargefamilyofdiverseproteinscharacterizedbyconservedannexinrepeatdomainsandtheabilitytobindnegativelychargedphos-pholipidsinacalcium-dependentmanner[7].AnxA2wasdownregulatedinasubsetofhumanOSmetastasesandmetastaticlines[45,165].TheactualroleofAnxA2insuppressingOSmetastasisremainstobeelucidated.Chemokinestromalcell-derivedfactor1(SDF-1)belongstocytokinelikeproteinsthat,throughbindingtotheirCXCRreceptors,playaroleincytoskeletonrear-rangement,adhesiontoendothelialcells,anddirectionalmigration[19].CXCR4/SDF-1isimportantintumorpro-gression[130,228].MigrationandadhesionofOScellswerepromotedbySDF-1treatment,whereasthedevelop-mentofpulmonarymetastasisafterinjectionofOScellsinamousemodelcouldbepreventedbytheadministrationofT134peptide,aninhibitorofCXCR4[191].PossibleLinksBetweenDefectiveOsteogenicDifferentiationandBoneTumorigenesisHumanOStumorsexhibitosteoblast-likefeatures,althoughthedifferentiationstatusofOStumorscanbeobservedwithinabroadrange,fromhighlydifferentiatedtopoorlydifferentiatedorundifferentiatedphenotypes[75].However,potentialcancerstemcellsresponsibleforOSdevelopmenthaveyettobeidentiﬁed.Understandingthemolecularmechanismunderlyingosteogenicdifferen-tiationwouldhelptounravelthemolecularpathogenesisofhumanOS.Osteogenesisresultsfromawell-coordinatedsequenceofeventsinvolvingepithelialmesenchymalinteraction,condensation,anddifferentiation(Fig.1A).Severalmajorsignalingpathways,suchWnt,BMP,FGF,andhedgehogsignaling,playanimportantroleinregu-latingosteogenicdifferentiation[58,134–136,203,204].Atthetranscriptionlevel,severaltranscriptionalfactorshavebeenidentiﬁedasimportantregulatorsofosteogeniclineagecommitmentandterminaldifferentiation.ThesetranscriptionalfactorsincludeRunx2,Osterix,ATF4,andTAZ[17,31,36,41,95,97–100,189,229,230,250,263,273].Amongthesefactors,Runx2playsanimportantroleandservesasahubtodirectprogenitorstoosteogeniclineage[38,39,82,96,114,129,171,173,187,270].Runx2isamemberoftheRunxclassoftranscriptionfactorsthatcontainahighlyconserved128aminoacidmotifconferringDNAbinding,protein-proteininteractions,andATPbindingactivities[38,39,82,96,114,129,171,173,187,270].Runx2-/-dieshortlyafterbirthanddem-onstratedacartilaginousskeletonwithcompleteabsenceofossiﬁcation.DespitethecartilaginousphenotypeintheRunx2-nullmice,histologicanalysisdemonstrateddelayedchondrocytematurationsuggestingtheimportanceofRunx2inchondrogenesisandosteogenesis.Additionally,whenRunx2isoverexpressedinchondrocytesviathechondrocyte-speciﬁctypeIIcollagenpromoter,itresultsinectopicchondrocytehypertrophyandendochondralossiﬁ-cation,therebydemonstratingtheimportanceofRunx2incontrollingdifferentiationofbothchondrocytesandosteoblasts[38,39,82,96,114,129,171,173,187,270].Runx2transcriptionalactivityisregulatedbynumeroustranscriptionalco-activatorsandcorepressors,includingitsinteractionwithRbprotein(seebelow).OScanberegardedasadifferentiationdiseasethatiscausedbygeneticandepigeneticdisruptionsofosteoblastterminaldifferentiation(Fig.1B).Thismodelissupportedbythefollowingfacts:First,OStumorsexhibitthechar-acteristicsofundifferentiatedosteoblasts[26,75,83,181,195,196,219,233,277].Second,differentiation-promotingagents(eg,PPARcagonistsand9-cis-retinoicacid)induceosteoblastdifferentiation[75,76].Third,RBcoactivatesRunx2throughdirectphysicalinteractionsatsitesofactivetranscription,andlossoffunctionofRBattenuatesterminalosteoblastdifferentiationinvitro[232].RBplaysessentialrolesinmanycellularprocessesincludingmesenchymaldifferentiation[70,72,116,245].Fourth,Runx2coordi-natesterminalcellcycleexitthroughinductionofp27KIP[1],whichinturnisrequiredfornormalbonedevelopmentandislostindedifferentiatedhumanOS[233].Lastly,osteogenicstimuli,suchasosteogenicBMPs,failedtopromotetheterminaldifferentiationofmostOScellsandratherenhancedOStumorgrowth,furtherhighlightingtheexistenceofpossibledifferentiationdefectsinOScells[75].Furthermore,inEwing’ssarcoma(ESW),EWS/ETS2120Tangetal.ClinicalOrthopaedicsandRelatedResearch123fusionproteinsblockdifferentiationalongosteogenicandadipogeniclineagesofmarrowstromalcells[238].Infact,expressionoftheEWS/FLI-1oncogeneinmurineprimarybone-derivedcellsresultsinEWS/FLI-1-dependent,Ewing’ssarcoma-liketumors[27].Conversely,uponEWS-FLI1silencing,someoftheESWcelllinescandifferentiatealongtheadipogenicorosteogeniclineageswhenstimu-latedwithappropriatedifferentiationcocktails[234].Takentogether,theseemergingdatastronglysuggestosteosar-comogenesismayberesultedfromdefectsinosteoblastdifferentiationpathway.DiscussionOsteosarcomasareaclinicallyandmolecularlyheteroge-neousgroupofmalignanciescharacterizedbyvaryingdegreesofmesenchymaldifferentiation.Thegeneticandepigeneticalterationsdescribedabovemayrepresentacross-sectionalendpointviewofOS.However,deﬁningtheirrolesinOSdevelopmenthasbeenhamperedbythecomplexityofthegeneticchangesandtherarityofOSsamples.Althoughosteosarcomatumorsdisplayabroadrangeofgeneticandmolecularalterations,mostalterationsFig.1A–B(A)Osteogenicdif-ferentiationisawell-coordinatedprocess.Mesenchymalstemcells(MSCs)cangiverisetoseverallineages,suchasmyocytes,adi-pocytes,chondrocytes,andosteocytes,withappropriatestimuli,presumablybyactivat-ingproperlineage-speciﬁcregulators,eg,MyoD,PPARc,Sox9,orRunx2/Osterix.Osteo-genicdifferentiationisatightlycontrolledprocess,whichcanbemonitoredbyusingalkalinephosphataseasanearlymarkerandosteocalcinandosteopontinaslatemarkers.(B)DisruptionofosteogenicdifferentiationmayleadtoOSdevelopment.Thedefectscausedbygenetic(eg,activationofoncogenesorinac-tivationofp53andRBtumorsuppressorgenes)andepigeneticalterationsmayoccuratdifferentstagesofosteogenicdifferentia-tion.ItisconceivabledefectsattheearlystagesmayleadtothedevelopmentofmoreaggressiveandundifferentiatedOS,orviceversa.Thecellsﬁlledwithblackcolorindicatecancer-initiatingcells.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2121123arenotfrequentlydetectedinthemajorityofosteosarcomatumors.Witharapidexpansionofourknowledgeaboutstemcellbiology,emergingevidencesuggestsosteosar-comamayberegardedasadifferentiationdiseasecausedbygeneticandepigeneticchangesthatinterruptosteoblastdifferentiationfrommesenchymalstemcells.Inthissurvey,weﬁrstreviewedthecurrentgeneticalterationsandmolecularbiologyofOS,andthenfocusedonthepossiblerelationshipbetweenosteogenicdifferen-tiationandbonetumorigenesis.BysearchingPubMedwithvariouskeywords,wefoundover20,000publicationsrel-evanttothetopic.Althoughweonlyconductedthesearchusingasingledatabase,PubMedrepresentsoneofthemostextensivedatabasesforbiomedicalsciences.WebelievemostoftherelevantandimportantﬁndingsrelatedtoOShavebeenincludedinthissingledatabasebutcannotexcludeotherinformationthatmightbefoundinotherdatabases(e.g.,EMBASE).Itisconceivablethat,atleastforasubsetofosteosar-comas,cancer-initiatingcellsmaysharefeaturesofacommittedosteoprogenitor.Tumorigenesismayinvolvedisruptionofmechanisms,appropriatelyconstraintheini-tiationofproliferationbytumorstemcells,orallowpersistentexpressionofstemcell-likefeaturesinapparentlypartiallycommittedcells.Thesimilaritiesbetweenstemcellpropertiesandthoseoftransformedcellsarestrikingasbothcelltypespossessunlimitedself-renewal,expresstel-omerase,andareundifferentiatedasdeﬁnedbytheabsenceoflineage-restrictedmarkers.Infact,asmallsubpopulationofself-renewingOScellsarecapableofformingsuspendedsphericalcellsandcolonies[55].TheseOScellsaswellastissuespecimensexpressactivatedSTAT3andthemarkergenesofpluripotentembryonicstem(ES)cells,Oct3/4andNanog[55].Insupportofthisnotion,OSisfrequentlyobservedinadolescence,astageofintensiveskeletalgrowthentailingincreasedosteoblastactivity.Stemcellsaremoreresistanttomutageniceventsthansomaticcells,inpartduetoenhancedapoptoticresponsestogenotoxicstressandDNAdamage.Theefﬁciencyofsuchprocessesappearsinverselyrelatedtothedegreeofterminaldifferentiation[231].Thus,futureinvestigationsshouldbedevotedtoidentifyingthekeydefectsintheosteoblastdifferentiationpathway,whichisalsoresponsibleforthedevelopmentofprimarybonetumors.Asoneofthemostimportantfactorsregulateosteoblastlineagecommitmentandexpansion,Runx2maybede-regulatedandplaysanimportantroleinOSdevelopment.Runx2levelsandfunctionarebiologicallylinkedtoacellgrowth-relatedG(1)transitioninosteoblasticcells[52].Runx2andhistonedeacetylase3-mediatedrepressionisbelievedtoallowhighexpressionofbonesialoprotein-abonematrixglycoproteinwhoseexpressioncoincideswithterminalosteoblasticdifferentiationandtheonsetofmineralization-indifferentiatinghumanosteoblastcells[122].Runx2ishyperphosphorylatedbyCDK1/cyclinBduringmitosis,anddynamicallyconvertedintoahypophosphorylatedformbyPP1/PP2A-dependentdephosphorylationaftermitosistosupportthepostmitoticregulationofRunx2targetgenes[201].AmorerecentstudyindicatesRunx2-mediatedactivationoftheBaxgeneincreasesosteosarcomacellsensitivitytoapoptosisandBaxasadirecttargetofRunx2,suggestingRunx2mayactasaproapoptoticfactorinosteosarcomacells[42].AnotherimportantfactorthatmayplayanimportantroleinosteogenicdifferentiationandbonetumorigenesisispRb.ThecellcycleregulatorypathwayregulatedbypRbisinactivatedinalmostallhumancancers,butindividualtumortypesseemtotargetspeciﬁccomponentstoachievethiseffect.AsdescribedinResults,pRbitselfisfrequentlyinactivatedinOS,andinheritedheterozygouslossoftheRBgeneconfersapproximatelya1000-foldgreaterinci-denceofOSthanthegeneralpopulation.SeverallinesofevidenceimplicatepRbinosteogenesisaspRbcoactivatesRunx2throughdirectphysicalinteractionsatsitesofactivetranscription,andlossoffunctionofpRbattenuatester-minalosteoblastdifferentiationinvitro[231].Runx2coordinatesterminalcellcycleexitthroughinductionoftheCDK2inhibitorp27KIP1,whichinturnisrequiredfornormalbonedevelopmentinvitroandinvivo,andislostindedifferentiatedhumanosteosarcomas[231].ItisalsopossiblepRbinﬂuencesosteoblastdifferentiationthroughothermechanismsinvolvingchromatinstructure.Thus,itwouldbeimportanttoinvestigatehowthederegulationofpRband/orRunx2functionsmayleadtothedevelopmentofbonesarcomas.Understandingthemolecularpathogenesisofhumanosteosarcomacouldultimatelyleadtothedevelopmentofdiagnosticandprognosticmarkers,aswellastargetedtherapeuticsforosteosarcomapatients.Dissectingthemolecularmechanismsthatcontrolosteoblastdifferentia-tionisimportantnotonlytounderstandnormalskeletogenesisandtopinpointpotentialdefectsresponsibleforOSdevelopmentbutalsotoimprovetheclinicalmanagementofhumanOS.Althoughpre-andpostopera-tivechemotherapieshaveimprovedthe5-yearsurvivalrateofOSpatients,recurrentand/ormetastaticOStumorsaremoreaggressiveandusuallyresistanttoconventionalcancertherapies.Inabroadersense,mostcurrentchemo-therapiesand/orradiationtherapiestargettherapidlyproliferativetumorcells,withlittleconsiderationofpromotingtumorcelldifferentiation.Itisconceivableacombinedtherapeuticapproachtargetingbothproliferationanddifferentiationphasesoftumorcellswouldbemoreefﬁcaciousandlesspronetoinducingchemoresistance[75,76,217,278].Thus,identiﬁcationofthecriticaldif-ferentiationdefectsinOStumorsmayleadtoarational2122Tangetal.ClinicalOrthopaedicsandRelatedResearch123designoftherapeuticstrategiesthatinduceterminaldif-ferentiationofOScellsthroughalternativedifferentiationpathwaysand/orbypassingthedifferentiationdefects.Thepotentiallyimportantroleofgeneticandepigeneticeventsinbothosteogenesisandbonetumorigenesisisnowrecognized.Ourcurrentknowledgeoftranscriptionalreg-ulationofosteoblastdifferentiationwillprovideimportantinsightsintothepotentialdefectsinosteogenicdifferenti-ationofOScells.FutureresearchshouldbedirectedtowardsidentifyingthesedifferentiationdefectsinOScells.ThisknowledgemayhelpusdevelopefﬁcaciousdifferentiationtherapiesforOSbyexploitingnoncellautonomoussignalstopromotedifferentiationstate.AcknowledgmentsWeapologizetotheinvestigatorswhoseorigi-nalworkcouldnotbecitedduetospaceconstraints.References1.AbramsonDH,EllsworthRM,KitchinFD,TungG.Secondnonoculartumorsinretinoblastomasurvivors.Aretheyradia-tion-induced?Ophthalmology.1984;91:1351–1355.2.AlonsoJ,Garcia-MiguelP,AbelairasJ,MendiolaM,PestanaA.AmicrosatelliteﬂuorescentmethodforlinkageanalysisinfamilialretinoblastomaanddeletiondetectionattheRB1locusinretinoblastomaandosteosarcoma.DiagnMolPathol.2001;10:9–14.3.AndreassenA,OyjordT,HovigE,HolmR,FlorenesVA,NeslandJM,MyklebostO,HoieJ,BrulandOS,BorresenAL,etal.p53abnormalitiesindifferentsubtypesofhumansarco-mas.CancerRes.1993;53:468–471.4.ArakiN,UchidaA,KimuraT,YoshikawaH,AokiY,UedaT,TakaiS,MikiT,OnoK.Involvementoftheretinoblastomageneinprimaryosteosarcomasandotherboneandsoft-tissuetumors.ClinOrthopRelatRes.1991;270:271–277.5.AueG,MuralidharB,SchwartzHS,ButlerMG.Telomeraseactivityinskeletalsarcomas.AnnSurgOncol.1998;5:627–634.6.BaekWK,ParkJW,LimJH,SuhSI,SuhMH,GabrielsonE,KwonTK.Molecularcloningandcharacterizationofthehumanbuddinguninhibitedbybenomyl(BUB3)promoter.Gene.2002;295:117–123.7.BalchC,DedmanJR.AnnexinsIIandVinhibitcellmigration.ExpCellRes.1997;237:259–263.8.BarkerN,CleversH.Catenins,Wntsignalingandcancer.Bioessays.2000;22:961–965.9.BarriosC,CastresanaJS,KreicbergsA.Clinicopathologiccor-relationsandshort-termprognosisinmusculoskeletalsarcomawithc-myconcogeneampliﬁcation.AmJClinOncol.1994;17:273–276.10.BarriosC,CastresanaJS,RuizJ,KreicbergsA.Ampliﬁcationofc-myconcogeneandabsenceofc-Ha-raspointmutationinhumanbonesarcoma.JOrthopRes.1993;11:556–563.11.BeedlesKE,SharpePT,WagnerEF,GrigoriadisAE.Aputativeroleforc-FosinthepathophysiologyofPaget’sdisease.JBoneMinerRes.1999;14Suppl2:21–28.12.BelchisDA,MeeceCA,BenkoFA,RoganPK,WilliamsRA,GockeCD.Lossofheterozygosityandmicrosatelliteinstabilityattheretinoblastomalocusinosteosarcomas.DiagnMolPathol.1996;5:214–219.13.BenassiMS,MolendiniL,GamberiG,RagazziniP,SollazzoMR,MerliM,AspJ,MagagnoliG,BalladelliA,BertoniF,PicciP.AlterationofpRb/p16/cdk4regulationinhumanoste-osarcoma.IntJCancer.1999;84:489–493.14.BeniniS,BaldiniN,ManaraMC,ChanoT,SerraM,RizziS,LolliniPL,PicciP,ScotlandiK.Redundancyofautocrineloopsinhumanosteosarcomacells.IntJCancer.1999;80:581–588.15.BernerJM,ForusA,ElkahlounA,MeltzerPS,FodstadO,MyklebostO.SeparateampliﬁedregionsencompassingCDK4andMDM2inhumansarcomas.GenesChromosomesCancer.1996;17:254–259.16.BernerJM,Meza-ZepedaLA,KoolsPF,ForusA,SchoenmakersEF,VandeVenWJ,FodstadO,MyklebostO.HMGIC,thegeneforanarchitecturaltranscriptionfactor,isampliﬁedandrearrangedinasubsetofhumansarcomas.Oncogene.1997;14:2935–2941.17.BialekP,KernB,YangX,SchrockM,SosicD,HongN,WuH,YuK,OrnitzDM,OlsonEN,JusticeMJ,KarsentyG.Atwistcodedeterminestheonsetofosteoblastdifferentiation.DevCell.2004;6:423–435.18.BjornlandK,FlatmarkK,PettersenS,AaasenAO,FodstadO,MaelandsmoGM.Matrixmetalloproteinasesparticipateinosteosarcomainvasion.JSurgRes.2005;127:151–156.19.BleulCC,FuhlbriggeRC,CasasnovasJM,AiutiA,SpringerTA.Ahighlyefﬁcaciouslymphocytechemoattractant,stromalcell-derivedfactor1(SDF-1).JExpMed.1996;184:1101–1109.20.BodeyB,GrogerAM,BodeyBJr.,SiegelSE,KaiserHE.Immunohistochemicaldetectionofp53proteinoverexpressioninprimaryhumanosteosarcomas.AnticancerRes.1997;17:493–498.21.BurrowS,AndrulisIL,PollakM,BellRS.Expressionofinsulin-likegrowthfactorreceptor,IGF-1,andIGF-2inprimaryandmetastaticosteosarcoma.JSurgOncol.1998;69:21–27.22.CadiganKM,NusseR.Wntsignaling:acommonthemeinanimaldevelopment.GenesDev.1997;11:3286–3305.23.CahillDP,KinzlerKW,VogelsteinB,LengauerC.Geneticinstabilityanddarwinianselectionintumours.TrendsCellBiol.1999;9:M57–60.24.CarboneM,RizzoP,ProcopioA,GiulianoM,PassHI,GebhardtMC,ManghamC,HansenM,MalkinDF,BushartG,PompettiF,PicciP,LevineAS,BergsagelJD,GarceaRL.SV40-likesequencesinhumanbonetumors.Oncogene.1996;13:527–535.25.CarlssonH,PeterssonS,EnerbackC.ClusteranalysisofS100geneexpressionandgenescorrelatingtopsoriasin(S100A7)expressionatdifferentstagesofbreastcancerdevelopment.IntJOncol.2005;27:1473–1481.26.CarpioL,GladuJ,GoltzmanD,RabbaniSA.InductionofosteoblastdifferentiationindexesbyPTHrPinMG-63cellsinvolvesmultiplesignalingpathways.AmJPhysiolEndocrinolMetab.2001;281:E489–499.27.Castillero-TrejoY,EliazerS,XiangL,RichardsonJA,IlariaRLJr.ExpressionoftheEWS/FLI-1oncogeneinmurineprimarybone-derivedcellsResultsinEWS/FLI-1-dependent,ewingsarcoma-liketumors.CancerRes.2005;65:8698–8705.28.CastresanaJS,RubioMP,GomezL,KreicbergsA,ZetterbergA,BarriosC.DetectionofTP53genemutationsinhumansar-comas.EurJCancer.1995;31A:735–738.29.ChandarN,BilligB,McMasterJ,NovakJ.Inactivationofp53geneinhumanandmurineosteosarcomacells.BrJCancer.1992;65:208–214.30.ChenCY,OlinerJD,ZhanQ,FornaceAJJr.,VogelsteinB,KastanMB.Interactionsbetweenp53andMDM2inamam-maliancellcyclecheckpointpathway.ProcNatlAcadSciUSA.1994;91:2684–2688.31.ChienKR,KarsentyG.Longevityandlineages:towardtheintegrativebiologyofdegenerativediseasesinheart,muscle,andbone.Cell.2005;120:533–544.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma212312332.ColeMD,McMahonSB.TheMyconcoprotein:acriticalevaluationoftransactivationandtargetgeneregulation.Onco-gene.1999;18:2916–2924.33.Cordon-CardoC.Mutationsofcellcycleregulators.Biologicalandclinicalimplicationsforhumanneoplasia.AmJPathol.1995;147:545–560.34.CormierJN,PollockRE.Softtissuesarcomas.CACancerJClin.2004;54:94–109.35.DeichmannM,BennerA,BockM,JackelA,UhlK,WaldmannV,NaherH.S100-Beta,melanoma-inhibitingactivity,andlactatedehydrogenasediscriminateprogressivefromnonprogressiveAmericanJointCommitteeonCancerstageIVmelanoma.JClinOncol.1999;17:1891–1896.36.DengZL,SharffKA,TangN,SongWX,LuoJXL,ChenJ,BennettE,ReidR.ManningD,XueA,MontagAG,LuuHH,HaydonRC,HeT-C.Regulationofosteogenicdifferentiationduringskeletaldevelopment.FrontiersinBiosci.2008;13:2001–2021.37.DiederichsS,BulkE,SteffenB,JiP,TickenbrockL,LangK,ZankerKS,MetzgerR,SchneiderPM,GerkeV,ThomasM,BerdelWE,ServeH,Muller-TidowC.S100familymembersandtrypsinogensarepredictorsofdistantmetastasisandsur-vivalinearly-stagenon-smallcelllungcancer.CancerRes.2004;64:5564–5569.38.DucyP,StarbuckM,PriemelM,ShenJ,PineroG,GeoffroyV,AmlingM,KarsentyG.ACbfa1-dependentgeneticpathwaycontrolsboneformationbeyondembryonicdevelopment.GenesDev.1999;13:1025–1036.39.DucyP,ZhangR,GeoffroyV,RidallAL,KarsentyG.Osf2/Cbfa1:atranscriptionalactivatorofosteoblastdifferentiation.Cell.1997;89:747–754.40.el-DeiryWS.Regulationofp53downstreamgenes.SeminCancerBiol.1998;8:345–357.41.ElefteriouF,BensonMD,SowaH,StarbuckM,LiuX,RonD,ParadaLF,KarsentyG.ATF4mediationofNF1functionsinosteoblastrevealsanutritionalbasisforcongenitalskeletaldysplasiae.CellMetab.2006;4:441–451.42.EliseevRA,DongYF,SampsonE,ZuscikMJ,SchwarzEM,O’KeefeRJ,RosierRN,DrissiMH.Runx2-mediatedactivationoftheBaxgeneincreasesosteosarcomacellsensitivitytoapoptosis.Oncogene.[Epubaheadofprint].Jan282008.43.ElkahlounAG,BittnerM,HoskinsK,GemmillR,MeltzerPS.Molecularcytogeneticcharacterizationandphysicalmappingof12q13–15ampliﬁcationinhumancancers.GenesChromosomesCancer.1996;17:205–214.44.ElkahlounAG,KrizmanDB,WangZ,HofmannTA,RoeB,MeltzerPS.Transcriptmappingina46-kbsequencedregionatthecoreof12q13.3ampliﬁcationinhumancancers.Genomics.1997;42:295–301.45.EmotoK,SawadaH,YamadaY,FujimotoH,TakahamaY,UenoM,TakayamaT,UchidaH,KamadaK,NaitoA,HiraoS,NakajimaY.AnnexinIIoverexpressioniscorrelatedwithpoorprognosisinhumangastriccarcinoma.AnticancerRes.2001;21:1339–1345.46.FerraciniR,DiRenzoMF,ScotlandiK,BaldiniN,OliveroM,LolliniP,CremonaO,CampanacciM,ComoglioPM.TheMet/HGFreceptorisover-expressedinhumanosteosarcomasandisactivatedbyeitheraparacrineoranautocrinecircuit.Oncogene.1995;10:739–749.47.FerrariC,BenassiS,PonticelliF,GamberiG,RagazziniP,PazzagliaL,BalladelliA,BertoniF,PicciP.RoleofMMP-9anditstissueinhibitorTIMP-1inhumanosteosarcoma:ﬁndingsin42patientsfollowedfor1–16years.ActaOrthopScand.2004;75:487–491.48.FeugeasO,GuriecN,Babin-BoilletotA,MarcellinL,SimonP,BabinS,ThyssA,HofmanP,TerrierP,KalifaC,Brunat-MentignyM,PatricotLM,OberlingF.LossofheterozygosityoftheRBgeneisapoorprognosticfactorinpatientswithosteo-sarcoma.JClinOncol.1996;14:467–472.49.ForusA,FlorenesVA,MaelandsmoGM,MeltzerPS,FodstadO,MyklebostO.Mappingofampliﬁcationunitsintheq13–14regionofchromosome12inhumansarcomas:someamplicadonotincludeMDM2.CellGrowthDiffer.1993;4:1065–1070.50.FranchiA,CalzolariA,ZampiG.Immunohistochemicaldetectionofc-fosandc-junexpressioninosseousandcarti-laginoustumoursoftheskeleton.VirchowsArch.1998;432:515–519.51.FuchsB,PritchardDJ.Etiologyofosteosarcoma.ClinOrthopRelatRes.2002;397:40–52.52.GalindoM,PratapJ,YoungDW,HovhannisyanH,ImHJ,ChoiJY,LianJB,SteinJL,SteinGS,vanWijnenAJ.Thebone-speciﬁcexpressionofRunx2oscillatesduringthecellcycletosupportaG1-relatedantiproliferativefunctioninosteoblasts.JBiolChem.2005;280:20274–20285.53.GamberiG,BenassiMS,BohlingT,RagazziniP,MolendiniL,SollazzoMR,PompettiF,MerliM,MagagnoliG,BalladelliA,PicciP.C-mycandc-fosinhumanosteosarcoma:prognosticvalueofmRNAandproteinexpression.Oncology.1998;55:556–563.54.GermanJ.Bloomsyndrome:amendelianprototypeofsomaticmutationaldisease.Medicine(Baltimore).1993;72:393–406.55.GibbsCP,KukekovVG,ReithJD,TchigrinovaO,SuslovON,ScottEW,GhivizzaniSC,IgnatovaTN,SteindlerDA.Stem-likecellsinbonesarcomas:implicationsfortumorigenesis.Neo-plasia.2005;7:967–976.56.GilesRH,vanEsJH,CleversH.CaughtupinaWntstorm:Wntsignalingincancer.BiochimBiophysActa.2003;1653:1–24.57.GilletteJM,ChanDC,Nielsen-PreissSM.Annexin2expressionisreducedinhumanosteosarcomametastases.JCellBiochem.2004;92:820–832.58.GlassDA2nd,KarsentyG.InvivoanalysisofWntsignalinginbone.Endocrinology.2007;148:2630–2634.59.GobbiG,SangiorgiL,LenziL,CasadeiR,CanaiderS,StrippoliP,LucarelliE,GhediniI,DonatiD,FabbriN,WarzechaJ,YeoungC,HelmanLJ,PicciP,CarinciP.SevenBMPsandalltheirreceptorsaresimultaneouslyexpressedinosteosarcomacells.IntJOncol.2002;20:143–147.60.GokgozN,WunderJS,MoussesS,EskandarianS,BellRS,AndrulisIL.Comparisonofp53mutationsinpatientswithlocalizedosteosarcomaandmetastaticosteosarcoma.Cancer.2001;92:2181–2189.61.GordonMD,NusseR.Wntsignaling:multiplepathways,multiplereceptors,andmultipletranscriptionfactors.JBiolChem.2006;281:22429–22433.62.GorlickR,AndersonP,AndrulisI,ArndtC,BeardsleyGP,BernsteinM,BridgeJ,CheungNK,DomeJS,EbbD,GardnerT,GebhardtM,GrierH,HansenM,HealeyJ,HelmanL,HockJ,HoughtonJ,HoughtonP,HuvosA,KhannaC,KieranM,KleinermanE,LadanyiM,LauC,MalkinD,MarinaN,MeltzerP,MeyersP,SchoﬁeldD,SchwartzC,SmithMA,ToretskyJ,TsokosM,WexlerL,WiggintonJ,WithrowS,SchoenfeldtM,AndersonB.Biologyofchildhoodosteogenicsarcomaandpotentialtargetsfortherapeuticdevelopment:meetingsummary.ClinCancerRes.2003;9:5442–5453.63.GorlickR,HuvosAG,HellerG,AledoA,BeardsleyGP,HealeyJH,MeyersPA.ExpressionofHER2/erbB-2correlateswithsurvivalinosteosarcoma.JClinOncol.1999;17:2781–2788.64.GotoA,KandaH,IshikawaY,MatsumotoS,KawaguchiN,MachinamiR,KatoY,KitagawaT.Associationoflossofheterozygosityatthep53locuswithchemoresistanceinosteo-sarcomas.JpnJCancerRes.1998;89:539–547.2124Tangetal.ClinicalOrthopaedicsandRelatedResearch12365.GotoM,MillerRW,IshikawaY,SuganoH.ExcessofrarecancersinWernersyndrome(adultprogeria).CancerEpidemiolBiomarkersPrev.1996;5:239–246.66.HaberDA.Splicingintosenescence:thecuriouscaseofp16andp19ARF.Cell.1997;91:555–558.67.HansenMF.Geneticandmolecularaspectsofosteosarcoma.JMusculoskeletNeuronalInteract.2002;2:554–560.68.HansenMF,CaveneeWK.Geneticsofcancerpredisposition.CancerRes.1987;47:5518–5527.69.HansenR,OrenM.p53;frominductivesignaltocellulareffect.CurrOpinGenetDev.1997;7:46–51.70.HarbourJW,DeanDC.TheRb/E2Fpathway:expandingrolesandemergingparadigms.GenesDev.2000;14:2393–2409.71.HarpioR,EinarssonR.S100proteinsascancerbiomarkerswithfocusonS100Binmalignantmelanoma.ClinBiochem.2004;37:512–518.72.HatakeyamaM,WeinbergRA.TheroleofRBincellcyclecontrol.ProgCellCycleRes.1995;1:9–19.73.HaydenJB,HoangBH.Osteosarcoma:basicscienceandclini-calimplications.OrthopClinNorthAm.2006;37:1–7.74.HaydonRC,DeyrupA,IshikawaA,HeckR,JiangW,ZhouL,FengT,KingD,ChengH,BreyerB,PeabodyT,SimonMA,MontagAG,HeTC.Cytoplasmicand/ornuclearaccumulationofthebeta-cateninproteinisafrequenteventinhumanosteo-sarcoma.IntJCancer.2002;102:338–342.75.HaydonRC,LuuHH,HeTC.Osteosarcomaandosteoblasticdifferentiation:anewperspectiveononcogenesis.ClinOrthopRelatRes.2007;454:237–246.76.HaydonRC,ZhouL,FengT,BreyerB,ChengH,JiangW,IshikawaA,PeabodyT,MontagA,SimonMA,HeTC.Nuclearreceptoragonistsaspotentialdifferentiationtherapyagentsforhumanosteosarcoma.ClinCancerRes.2002;8:1288–1294.77.HelmanLJ,MeltzerP.Mechanismsofsarcomadevelopment.NatRevCancer.2003;3:685–694.78.HicksonID.RecQhelicases:caretakersofthegenome.NatRevCancer.2003;3:169–178.79.HimelsteinBP.Osteosarcomaandotherbonecancers.CurrOpinOncol.1998;10:326–333.80.HoangBH,KuboT,HealeyJH,SowersR,MazzaB,YangR,HuvosAG,MeyersPA,GorlickR.ExpressionofLDLreceptor-relatedprotein5(LRP5)asanovelmarkerfordiseasepro-gressioninhigh-gradeosteosarcoma.IntJCancer.2004;109:106–111.81.HoangBH,KuboT,HealeyJH,YangR,NathanSS,KolbEA,MazzaB,MeyersPA,GorlickR.Dickkopf3inhibitsinvasionandmotilityofSaos-2osteosarcomacellsbymodulatingtheWnt-beta-cateninpathway.CancerRes.2004;64:2734–2739.82.HongJH,HwangES,McManusMT,AmsterdamA,TianY,KalmukovaR,MuellerE,BenjaminT,SpiegelmanBM,SharpPA,HopkinsN,YaffeMB.TAZ,atranscriptionalmodulatorofmesenchymalstemcelldifferentiation.Science.2005;309:1074–1078.83.HongSH,KadosawaT,NozakiK,MochizukiM,MatsunagaS,NishimuraR,SasakiN.Invitroretinoid-inducedgrowthinhi-bitionandmorphologicdifferentiationofcanineosteosarcomacells.AmJVetRes.2000;61:69–73.84.HornebeckW,LambertE,PetitfrereE,BernardP.Beneﬁcialanddetrimentalinﬂuencesoftissueinhibitorofmetallopro-teinase-1(TIMP-1)intumorprogression.Biochimie.2005;87:377–383.85.HorstmannMA,PoslM,ScholzRB,AndereggB,SimonP,BaumgaertlK,DellingG,KabischH.FrequentreductionorlossofDCCgeneexpressioninhumanosteosarcoma.BrJCancer.1997;75:1309–1317.86.HughesAE,RalstonSH,MarkenJ,BellC,MacPhersonH,WallaceRG,vanHulW,WhyteMP,NakatsukaK,HovyL,AndersonDM.MutationsinTNFRSF11A,affectingthesignalpeptideofRANK,causefamilialexpansileosteolysis.NatGenet.2000;24:45–48.87.HungJ,AndersonR.p53:functions,mutationsandsarcomas.ActaOrthopScandSuppl.1997;273:68–73.88.HuvosAG,WoodardHQ,CahanWG,HiginbothamNL,StewartFW,ButlerA,BretskySS.Postradiationosteogenicsarcomaofboneandsofttissues.Aclinicopathologicstudyof66patients.Cancer.1985;55:1244–1255.89.IwaoK,MiyoshiY,NawaG,YoshikawaH,OchiT,NakamuraY.Frequentbeta-cateninabnormalitiesinboneandsoft-tissuetumors.JpnJCancerRes.1999;90:205–209.90.IwayaK,OgawaH,KurodaM,IzumiM,IshidaT,MukaiK.Cytoplasmicand/ornuclearstainingofbeta-cateninisassociatedwithlungmetastasis.ClinExpMetastasis.2003;20:525–529.91.JinY,YangLJ.Immunohistochemicalanalysisofbonemor-phogeneticprotein(BMP)inosteosarcoma.JOralPatholMed.1990;19:152–154.92.JungST,MoonES,SeoHY,KimJS,KimGJ,KimYK.ExpressionandsigniﬁcanceofTGF-betaisoformandVEGFinosteosarcoma.Orthopedics.2005;28:755–760.93.KanoeH,NakayamaT,MurakamiH,HosakaT,YamamotoH,NakashimaY,TsuboyamaT,NakamuraT,SasakiMS,ToguchidaJ.AmpliﬁcationoftheCDK4geneinsarcomas:tumorspeciﬁcityandrelationshipwiththeRBgenemutation.AnticancerRes.1998;18:2317–2321.94.KansaraM,ThomasDM.Molecularpathogenesisofosteosar-coma.DNACellBiol.2007;26:1–18.95.KarsentyG.Boneformationandfactorsaffectingthisprocess.MatrixBiol.2000;19:85–89.96.KarsentyG.RoleofCbfa1inosteoblastdifferentiationandfunction.SeminCellDevBiol.2000;11:343–346.97.KarsentyG.Centralcontrolofboneformation.AdvNephrolNeckerHosp.2001;31:119–133.98.KarsentyG.Geneticcontrolofskeletaldevelopment.NovartisFoundSymp.2001;232:6–17;discussion17–22.99.KarsentyG.Thecomplexitiesofskeletalbiology.Nature.2003;423:316–318.100.KarsentyG,WagnerEF.Reachingageneticandmolecularunderstandingofskeletaldevelopment.DevCell.2002;2:389–406.101.KeelSB,JaffeKA,PeturNielsenG,RosenbergAE.Ortho-paedicimplant-relatedsarcoma:astudyoftwelvecases.ModPathol.2001;14:969–977.102.Kempf-BielackB,BielackSS,JurgensH,BranscheidD,BerdelWE,ExnerGU,GobelU,HelmkeK,JundtG,KabischH,KevricM,KlingebielT,KotzR,MaasR,SchwarzR,SemikM,TreunerJ,ZoubekA,WinklerK.Osteosarcomarelapseaftercombinedmodalitytherapy:ananalysisofunselectedpatientsintheCooperativeOsteosarcomaStudyGroup(COSS).JClinOncol.2005;23:559–568.103.KhanJ,WeiJS,RingnerM,SaalLH,LadanyiM,WestermannF,BertholdF,SchwabM,AntonescuCR,PetersonC,MeltzerPS.Classiﬁcationanddiagnosticpredictionofcancersusinggeneexpressionproﬁlingandartiﬁcialneuralnetworks.NatMed.2001;7:673–679.104.KhannaC,KhanJ,NguyenP,PrehnJ,CaylorJ,YeungC,TrepelJ,MeltzerP,HelmanL.Metastasis-associateddiffer-encesingeneexpressioninamurinemodelofosteosarcoma.CancerRes.2001;61:3750–3759.105.KhannaC,PrehnJ,YeungC,CaylorJ,TsokosM,HelmanL.Anorthotopicmodelofmurineosteosarcomawithclonallyrelatedvariantsdifferinginpulmonarymetastaticpotential.ClinExpMetastasis.2000;18:261–271.106.KhannaC,WanX,BoseS,CassadayR,OlomuO,MendozaA,YeungC,GorlickR,HewittSM,HelmanLJ.Themembrane-Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2125123cytoskeletonlinkerezrinisnecessaryforosteosarcomametas-tasis.NatMed.2004;10:182–186.107.KhatibZA,MatsushimeH,ValentineM,ShapiroDN,SherrCJ,LookAT.CoampliﬁcationoftheCDK4genewithMDM2andGLIinhumansarcomas.CancerRes.1993;53:5535–5541.108.KimH,KwakNJ,LeeJY,ChoiBH,LimY,KoYJ,KimYH,HuhPW,LeeKH,RhaHK,WangYP.MerlinneutralizestheinhibitoryeffectofMdm2onp53.JBiolChem.2004;279:7812–7818.109.KimHS,ParkYB,OhJH,JeongJ,KimCJ,LeeSH.ExpressionofCD44isoformscorrelateswiththemetastaticpotentialofosteosarcoma.ClinOrthopRelatRes.2002;396:184–190.110.KimJB,LeuchtP,LamK,LuppenC,TenBergeD,NusseR,HelmsJA.Boneregenerationisregulatedbywntsignaling.JBoneMinerRes.2007;22:1913–1923.111.KitchinFD,EllsworthRM.Pleiotropiceffectsofthegeneforretinoblastoma.JMedGenet.1974;11:244–246.112.KleihuesP,SchaubleB,zurHausenA,EsteveJ,OhgakiH.Tumorsassociatedwithp53germlinemutations:asynopsisof91families.AmJPathol.1997;150:1–13.113.KloenP,GebhardtMC,Perez-AtaydeA,RosenbergAE,SpringﬁeldDS,GoldLI,MankinHJ.Expressionoftransform-inggrowthfactor-beta(TGF-beta)isoformsinosteosarcomas:TGF-beta3isrelatedtodiseaseprogression.Cancer.1997;80:2230–2239.114.KomoriT,YagiH,NomuraS,YamaguchiA,SasakiK,DeguchiK,ShimizuY,BronsonRT,GaoYH,InadaM,SatoM,OkamotoR,KitamuraY,YoshikiS,KishimotoT.TargeteddisruptionofCbfa1resultsinacompletelackofboneformationowingtomaturationalarrestofosteoblasts.Cell.1997;89:755–764.115.KoolsPF,VandeVenWJ.Ampliﬁcationofarearrangedformofthehigh-mobilitygroupproteingeneHMGICinOsA-CIosteosarcomacells.CancerGenetCytogenet.1996;91:1–7.116.KorenjakM,BrehmA.E2F-Rbcomplexesregulatingtran-scriptionofgenesimportantfordifferentiationanddevelopment.CurrOpinGenetDev.2005;15:520–527.117.KruzelockRP,MurphyEC,StrongLC,NaylorSL,HansenMF.Localizationofanoveltumorsuppressorlocusonhumanchromosome3qimportantinosteosarcomatumorigenesis.CancerRes.1997;57:106–109.118.KuryuM,OzakiT,NishidaK,ShibaharaM,KawaiA,InoueH.ExpressionofCD44variantsinosteosarcoma.JCancerResClinOncol.1999;125:646–652.119.LadanyiM,ChaC,LewisR,JhanwarSC,HuvosAG,HealeyJH.MDM2geneampliﬁcationinmetastaticosteosarcoma.CancerRes.1993;53:16–18.120.LadanyiM,ParkCK,LewisR,JhanwarSC,HealeyJH,HuvosAG.SporadicampliﬁcationoftheMYCgeneinhumanosteo-sarcomas.DiagnMolPathol.1993;2:163–167.121.LallemandD,CurtoM,SaotomeI,GiovanniniM,McClatcheyAI.NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev.2003;17:1090–1100.122.LamourV,DetryC,SanchezC,HenrotinY,CastronovoV,BellahceneA.Runx2-andhistonedeacetylase3-mediatedrepressionisrelievedindifferentiatinghumanosteoblastcellstoallowhighbonesialoproteinexpression.JBiolChem.2007;282:36240–36249.123.LarsenCJ.p16INK4a:agenewithadualcapacitytoencodeunrelatedproteinsthatinhibitcellcycleprogression.Oncogene.1996;12:2041–2044.124.LeachFS,TokinoT,MeltzerP,BurrellM,OlinerJD,SmithS,HillDE,SidranskyD,KinzlerKW,VogelsteinB.p53MutationandMDM2ampliﬁcationinhumansofttissuesarcomas.CancerRes.1993;53(10Suppl):2231–2234.125.LednickyJA,StewartAR,JenkinsJJ3rd,FinegoldMJ,ButelJS.SV40DNAinhumanosteosarcomasshowssequencevari-ationamongT-antigengenes.IntJCancer.1997;72:791–800.126.LevineAJ.p53,thecellulargatekeeperforgrowthanddivision.Cell.1997;88:323–331.127.LewisVO.What’snewinmusculoskeletaloncology.JBoneJointSurgAm.2007;89:1399–1407.128.LiFP,FraumeniJFJr,MulvihillJJ,BlattnerWA,DreyfusMG,TuckerMA,MillerRW.Acancerfamilysyndromeintwenty-fourkindreds.CancerRes.1988;48:5358–5362.129.LianJB,SteinGS,JavedA,vanWijnenAJ,SteinJL,MontecinoM,HassanMQ,GaurT,LengnerCJ,YoungDW.Networksandhubsforthetranscriptionalcontrolofosteoblas-togenesis.RevEndocrMetabDisord.2006;7:1–16.130.LiburaJ,DrukalaJ,MajkaM,TomescuO,NavenotJM,KuciaM,MarquezL,PeiperSC,BarrFG,Janowska-WieczorekA,RatajczakMZ.CXCR4-SDF-1signalingisactiveinrhabdo-myosarcomacellsandregulateslocomotion,chemotaxis,andadhesion.Blood.2002;100:2597–2606.131.LoganCY,NusseR.TheWntsignalingpathwayindevelop-mentanddisease.AnnuRevCellDevBiol.2004;20:781–810.132.LonardoF,UedaT,HuvosAG,HealeyJ,LadanyiM.p53andMDM2alterationsinosteosarcomas:correlationwithclinico-pathologicfeaturesandproliferativerate.Cancer.1997;79:1541–1547.133.Lopez-GuerreroJA,Lopez-GinesC,PellinA,CardaC,Llombart-BoschA.DeregulationoftheG1toS-phasecellcyclecheckpointisinvolvedinthepathogenesisofhumanosteosar-coma.DiagnMolPathol.2004;13:81–91.134.LuoJ,ChenJ,DengZL,LuoX,SongWX,SharffKA,TangN,HaydonRC,LuuHH,HeTC.Wntsignalingandhumandis-eases:whatarethetherapeuticimplications?LabInvest.2007;87:97–103.135.LuoJ,SunMH,KangQ,PengY,JiangW,LuuHH,LuoQ,ParkJY,LiY,HaydonRC,HeTC.Genetherapyforboneregeneration.CurrGeneTher.2005;5:167–179.136.LuuHH,SongWX,LuoX,ManningD,LuoJ,DengZL,SharffKA,MontagAG,HaydonRC,HeTC.Distinctrolesofbonemorphogeneticproteinsinosteogenicdifferentiationofmesen-chymalstemcells.JOrthopRes.2007;25:665–677.137.LuuHH,ZhangR,HaydonRC,RayburnE,KangQ,SiW,ParkJK,WangH,PengY,JiangW,HeTC.Wnt/beta-cateninsig-nalingpathwayasanovelcancerdrugtarget.CurrCancerDrugTargets.2004;4:653–671.138.LuuHH,ZhouL,HaydonRC,DeyrupAT,MontagAG,HuoD,HeckR,HeizmannCW,PeabodyTD,SimonMA,HeTC.IncreasedexpressionofS100A6isassociatedwithdecreasedmetastasisandinhibitionofcellmigrationandanchorageindependentgrowthinhumanosteosarcoma.CancerLett.2005;229:135–148.139.MacEwenEG,PastorJ,KutzkeJ,TsanR,KurzmanID,ThammDH,WilsonM,RadinskyR.IGF-1receptorcontributestothemalignantphenotypeinhumanandcanineosteosarcoma.JCellBiochem.2004;92:77–91.140.MaelandsmoGM,BernerJM,FlorenesVA,ForusA,HovigE,FodstadO,MyklebostO.HomozygousdeletionfrequencyandexpressionlevelsoftheCDKN2geneinhumansarcomas–relationshiptoampliﬁcationandmRNAlevelsofCDK4andCCND1.BrJCancer.1995;72:393–398.141.MaitraA,RobertsH,WeinbergAG,GeradtsJ.Lossofp16(INK4a)expressioncorrelateswithdecreasedsurvivalinpediatricosteosarcomas.IntJCancer.2001;95:34–38.142.MakitieT,CarpenO,VaheriA,KivelaT.Ezrinasaprognosticindicatoranditsrelationshiptotumorcharacteristicsinuvealmalignantmelanoma.InvestOphthalmolVisSci.2001;42:2442–2449.2126Tangetal.ClinicalOrthopaedicsandRelatedResearch123143.MaliakalJC,AsahinaI,HauschkaPV,SampathTK.Osteogenicprotein-1(BMP-7)inhibitscellproliferationandstimulatestheexpressionofmarkerscharacteristicofosteoblastphenotypeinratosteosarcoma(17/2.8)cells.GrowthFactors.1994;11:227–234.144.MalkinD,JollyKW,BarbierN,LookAT,FriendSH,GebhardtMC,AndersenTI,BorresenAL,LiFP,GarberJ,etal.Germlinemutationsofthep53tumor-suppressorgeneinchildrenandyoungadultswithsecondmalignantneoplasms.NEnglJMed.1992;326:1309–1315.145.MalkinD,LiFP,StrongLC,FraumeniJFJr,NelsonCE,KimDH,KasselJ,GrykaMA,BischoffFZ,TainskyMA,etal.Germlinep53mutationsinafamilialsyndromeofbreastcan-cer,sarcomas,andotherneoplasms.Science.1990;250:1233–1238.146.MarinaN,GebhardtM,TeotL,GorlickR.Biologyandthera-peuticadvancesforpediatricosteosarcoma.Oncologist.2004;9:422–441.147.MarkRJ,PoenJ,TranLM,FuYS,SelchMT,ParkerRG.Postirradiationsarcomas.Asingle-institutionstudyandreviewoftheliterature.Cancer.1994;73:2653–2662.148.MartinTA,HarrisonG,ManselRE,JiangWG.TheroleoftheCD44/ezrincomplexincancermetastasis.CritRevOncolHematol.2003;46:165–186.149.MassagueJ.TGF-betasignaltransduction.AnnuRevBiochem.1998;67:753–791.150.MassagueJ,ChenYG.ControllingTGF-betasignaling.GenesDev.2000;14:627–644.151.MassagueJ,WottonD.TranscriptionalcontrolbytheTGF-beta/Smadsignalingsystem.EmboJ.2000;19:1745–1754.152.MasudaH,MillerC,KoefﬂerHP,BattiforaH,ClineMJ.Rearrangementofthep53geneinhumanosteogenicsarcomas.ProcNatlAcadSciUSA.1987;84:7716–7719.153.McClatcheyAI.NeuroﬁbromatosistypeII:mousemodelsrevealbroadrolesintumorigenesisandmetastasis.MolMedToday.2000;6:252–253.154.McClatcheyAI,GiovanniniM.Membraneorganizationandtumorigenesis–theNF2tumorsuppressor,Merlin.GenesDev.2005;19:2265–2277.155.McClatcheyAI,SaotomeI,MercerK,CrowleyD,GusellaJF,BronsonRT,JacksT.MiceheterozygousforamutationattheNf2tumorsuppressorlocusdeveloparangeofhighlymetastatictumors.GenesDev.1998;12:1121–1133.156.McIntyreJF,Smith-SorensenB,FriendSH,KassellJ,BorresenAL,YanYX,RussoC,SatoJ,BarbierN,MiserJ,etal.Germlinemutationsofthep53tumorsuppressorgeneinchil-drenwithosteosarcoma.JClinOncol.1994;12:925–930.157.McNairnJD,DamronTA,LandasSK,AmbroseJL,ShrimptonAE.InheritanceofosteosarcomaandPaget’sdiseaseofbone:afamiliallossofheterozygositystudy.JMolDiagn.2001;3:171–177.158.Melo-JuniorMR,FilhoJL,CavalcantiCL,PatuVJ,BeltraoEI,CarvalhoLB.DetectionofS100proteinfromprostaticcancerpatientsusinganti-S100proteinantibodyimmobilizedonPOS-PVAdiscs.BiotechnolBioeng.2007;97:182–187.159.MeltzerPS,JankowskiSA,DalCinP,SandbergAA,PazIB,CocciaMA.IdentiﬁcationandcloningofanovelampliﬁedDNAsequenceinhumanmalignantﬁbroushistiocytomaderivedfromaregionofchromosome12frequentlyrearrangedinsofttissuetumors.CellGrowthDiffer.1991;2:495–501.160.MendozaS,DavidH,GaylordGM,MillerCW.Alleliclossat10q26inosteosarcomaintheregionoftheBUB3andFGFR2genes.CancerGenetCytogenet.2005;158:142–147.161.MendozaSM,KonishiT,MillerCW.IntegrationofSV40inhumanosteosarcomaDNA.Oncogene.1998;17:2457–2462.162.MillerCW,AsloA,CampbellMJ,KawamataN,LampkinBC,KoefﬂerHP.Alterationsofthep15,p16,andp18genesinosteosarcoma.CancerGenetCytogenet.1996;86:136–142.163.MillerCW,AsloA,TsayC,SlamonD,IshizakiK,ToguchidaJ,YamamuroT,LampkinB,KoefﬂerHP.Frequencyandstructureofp53rearrangementsinhumanosteosarcoma.CancerRes.1990;50:7950–7954.164.MillerCW,AsloA,WonA,TanM,LampkinB,KoefﬂerHP.Alterationsofthep53,RbandMDM2genesinosteosarcoma.JCancerResClinOncol.1996;122:559–565.165.MintzMB,SowersR,BrownKM,HilmerSC,MazzaB,HuvosAG,MeyersPA,LaﬂeurB,McDonoughWS,HenryMM,RamseyKE,AntonescuCR,ChenW,HealeyJH,DaluskiA,BerensME,MacdonaldTJ,GorlickR,StephanDA.Anexpressionsignatureclassiﬁeschemotherapy-resistantpediatricosteosarcoma.CancerRes.2005;65:1748–1754.166.MolendiniL,BenassiMS,MagagnoliG,MerliM,SollazzoMR,RagazziniP,GamberiG,FerrariC,BalladelliA,BacchiniP,PicciP.Prognosticsigniﬁcanceofcyclinexpressioninhumanosteosarcoma.IntJOncol.1998;12:1007–1011.167.MomandJ,JungD,WilczynskiS,NilandJ.TheMDM2geneampliﬁcationdatabase.NucleicAcidsRes.1998;26:3453–3459.168.MotoyamaJ,LiuJ,MoR,DingQ,PostM,HuiCC.EssentialfunctionofGli2andGli3intheformationoflung,tracheaandoesophagus.NatGenet.1998;20:54–57.169.MoussesS,McAuleyL,BellRS,KandelR,AndrulisIL.Molecularandimmunohistochemicalidentiﬁcationofp53alterationsinboneandsofttissuesarcomas.ModPathol.1996;9:1–6.170.MulliganLM,MatlashewskiGJ,ScrableHJ,CaveneeWK.Mechanismsofp53lossinhumansarcomas.ProcNatlAcadSciUSA.1990;87:5863–5867.171.MundlosS,OttoF,MundlosC,MullikenJB,AylsworthAS,AlbrightS,LindhoutD,ColeWG,HennW,KnollJH,OwenMJ,MertelsmannR,ZabelBU,OlsenBR.MutationsinvolvingthetranscriptionfactorCBFA1causecleidocranialdysplasia.Cell.1997;89:773–779.172.NakaT,IwamotoY,ShinoharaN,UshijimaM,ChumanH,TsuneyoshiM.Expressionofc-metproto-oncogeneproduct(c-MET)inbenignandmalignantbonetumors.ModPathol.1997;10:832–838.173.NakashimaK,ZhouX,KunkelG,ZhangZ,DengJM,BehringerRR,deCrombruggheB.Thenovelzincﬁnger-containingtranscriptionfactorosterixisrequiredforosteoblastdifferenti-ationandboneformation.Cell.2002;108:17–29.174.NakayamaT,ToguchidaJ,WadayamaB,KanoeH,KotouraY,SasakiMS.MDM2geneampliﬁcationinboneandsoft-tissuetumors:associationwithtumorprogressionindifferentiatedadipose-tissuetumors.IntJCancer.1995;64:342–346.175.NathrathMH,KuosaiteV,RosemannM,KremerM,PorembaC,WakanaS,YanagiM,NathrathWB,HoﬂerH,ImaiK,AtkinsonMJ.Twonoveltumorsuppressorgenelocionchro-mosome6qand15qinhumanosteosarcomaidentiﬁedthroughcomparativestudyofallelicimbalancesinmouseandman.Oncogene.2002;21:5975–5980.176.NelsonWJ,NusseR.ConvergenceofWnt,beta-catenin,andcadherinpathways.Science.2004;303:1483–1487.177.NesbitCE,TersakJM,ProchownikEV.MYConcogenesandhumanneoplasticdisease.Oncogene.1999;18:3004–3016.178.NevinsJR,LeoneG,DeGregoriJ,JakoiL.RoleoftheRb/E2Fpathwayincellgrowthcontrol.JCellPhysiol.1997;173:233–236.179.NielsenGP,BurnsKL,RosenbergAE,LouisDN.CDKN2Agenedeletionsandlossofp16expressionoccurinosteosarco-masthatlackRBalterations.AmJPathol.1998;153:159–163.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2127123180.Noble-TophamSE,BurrowSR,EppertK,KandelRA,MeltzerPS,BellRS,AndrulisIL.SASisampliﬁedpredominantlyinsurfaceosteosarcoma.JOrthopRes.1996;14:700–705.181.NozakiK,KadosawaT,NishimuraR,MochizukiM,TakahashiK,SasakiN.1,25-DihydroxyvitaminD3,recombinanthumantransforminggrowthfactor-beta1,andrecombinanthumanbonemorphogeneticprotein-2induceinvitrodifferentiationofcanineosteosarcomacells.JVetMedSci.1999;61:649–656.182.NusseR.TheWntgenefamilyintumorigenesisandinnormaldevelopment.JSteroidBiochemMolBiol.1992;43:9–12.183.NusseR.Wntsignalingindiseaseandindevelopment.CellRes.2005;15:28–32.184.OlinerJD,KinzlerKW,MeltzerPS,GeorgeDL,VogelsteinB.Ampliﬁcationofageneencodingap53-associatedproteininhumansarcomas.Nature.1992;358:80–83.185.OlinerJD,PietenpolJA,ThiagalingamS,GyurisJ,KinzlerKW,VogelsteinB.OncoproteinMDM2concealstheactivationdomainoftumoursuppressorp53.Nature.1993;362:857–860.186.OliveiraP,NogueiraM,PintoA,AlmeidaMO.Analysisofp53expressioninosteosarcomaofthejaw:correlationwithclini-copathologicandDNAploidyﬁndings.HumPathol.1997;28:1361–1365.187.OttoF,ThornellAP,CromptonT,DenzelA,GilmourKC,RosewellIR,StampGW,BeddingtonRS,MundlosS,OlsenBR,SelbyPB,OwenMJ.Cbfa1,acandidategeneforcleido-cranialdysplasiasyndrome,isessentialforosteoblastdifferentiationandbonedevelopment.Cell.1997;89:765–771.188.ParkBH,BreyerB,HeTC.Peroxisomeproliferator-activatedreceptors:rolesintumorigenesisandchemopreventioninhumancancer.CurrOpinOncol.2001;13:78–83.189.PatelMS,KarsentyG.RegulationofboneformationandvisionbyLRP5.NEnglJMed.2002;346:1572–1574.190.PedrocchiM,SchaferBW,MuellerH,EppenbergerU,Heiz-mannCW.ExpressionofCa(2+)-bindingproteinsoftheS100familyinmalignanthumanbreast-cancercelllinesandbiopsysamples.IntJCancer.1994;57:684–690.191.PerissinottoE,CavalloniG,LeoneF,FonsatoV,MitolaS,GrignaniG,SurrentiN,SangioloD,BussolinoF,PiacibelloW,AgliettaM.Involvementofchemokinereceptor4/stromalcell-derivedfactor1systemduringosteosarcomatumorprogression.ClinCancerRes.2005;11(2Pt1):490–497.192.PomerantzJ,Schreiber-AgusN,LiegeoisNJ,SilvermanA,AllandL,ChinL,PotesJ,ChenK,OrlowI,LeeHW,Cordon-CardoC,DePinhoRA.TheInk4atumorsuppressorgeneproduct,p19Arf,interactswithMDM2andneutralizesMDM2’sinhibitionofp53.Cell.1998;92:713–723.193.PompettiF,RizzoP,SimonRM,FreidlinB,MewDJ,PassHI,PicciP,LevineAS,CarboneM.Oncogenealterationsinpri-mary,recurrent,andmetastatichumanbonetumors.JCellBiochem.1996;63:37–50.194.PorterDE,HoldenST,SteelCM,CohenBB,WallaceMR,ReidR.AsigniﬁcantproportionofpatientswithosteosarcomamaybelongtoLi-Fraumenicancerfamilies.JBoneJointSurgBr.1992;74:883–886.195.PostiglioneL,DiDomenicoG,Giordano-LanzaG,LadoganaP,TuranoM,CastaldoC,DiMeglioF,CocozzaS,MontagnaniS.Effectofhumangranulocytemacrophage-colonystimulatingfactorondifferentiationandapoptosisofthehumanosteosar-comacelllineSaOS-2.EurJHistochem.2003;47:309–316.196.PostiglioneL,DomenicoGD,MontagnaniS,SpignaGD,SalzanoS,CastaldoC,RamagliaL,SbordoneL,RossiG.Granulocyte-macrophagecolony-stimulatingfactor(GM-CSF)inducestheosteoblasticdifferentiationofthehumanosteosar-comacelllineSaOS-2.CalcifTissueInt.2003;72:85–97.197.PovelonesM,NusseR.Wntsignallingseesspots.NatCellBiol.2002;4:E249–250.198.QuelleDE,ZindyF,AshmunRA,SherrCJ.AlternativereadingframesoftheINK4atumorsuppressorgeneencodetwounre-latedproteinscapableofinducingcellcyclearrest.Cell.1995;83:993–1000.199.RadigK,Schneider-StockR,HaeckelC,NeumannW,RoessnerA.p53genemutationsinosteosarcomasoflow-grademalig-nancy.HumPathol.1998;29:1310–1316.200.RagazziniP,GamberiG,BenassiMS,OrlandoC,SestiniR,FerrariC,MolendiniL,SollazzoMR,MerliM,MagagnoliG,BertoniF,BohlingT,PazzagliM,PicciP.AnalysisofSASgeneandCDK4andMDM2proteinsinlow-gradeosteosarcoma.CancerDetectPrev.1999;23:129–136.201.RajgopalA,YoungDW,MujeebKA,SteinJL,LianJB,vanWijnenAJ,SteinGS.MitoticcontrolofRUNX2phosphoryla-tionbybothCDK1/cyclinBkinaseandPP1/PP2Aphosphataseinosteoblasticcells.JCellBiochem.2007;100:1509–1517.202.ReifenbergerG,ReifenbergerJ,IchimuraK,MeltzerPS,CollinsVP.Ampliﬁcationofmultiplegenesfromchromosomalregion12q13–14inhumanmalignantgliomas:preliminarymappingoftheampliconsshowspreferentialinvolvementofCDK4,SAS,andMDM2.CancerRes.1994;54:4299–4303.203.ReyaT,CleversH.Wntsignallinginstemcellsandcancer.Nature.2005;434:843–850.204.ReyaT,MorrisonSJ,ClarkeMF,WeissmanIL.Stemcells,cancer,andcancerstemcells.Nature.2001;414:105–111.205.RobertsWM,DouglassEC,PeiperSC,HoughtonPJ,LookAT.Ampliﬁcationofthegligeneinchildhoodsarcomas.CancerRes.1989;49:5407–5413.206.RomanoJW,EhrhartJC,DuthuA,KimCM,AppellaE,MayP.Identiﬁcationandcharacterizationofap53genemutationinahumanosteosarcomacellline.Oncogene.1989;4:1483–1488.207.RongS,JeffersM,ResauJH,TsarfatyI,OskarssonM,VandeWoudeGF.Metexpressionandsarcomatumorigenicity.CancerRes.1993;53:5355–5360.208.RutherU,KomitowskiD,SchubertFR,WagnerEF.c-fosexpressioninducesbonetumorsintransgenicmice.Oncogene.1989;4:861–865.209.SalamaI,MalonePS,MihaimeedF,JonesJL.AreviewoftheS100proteinsincancer.EurJSurgOncol.[EpubJun132007].2008;34:357–364.210.SandbergAA,BridgeJA.Updatesonthecytogeneticsandmoleculargeneticsofboneandsofttissuetumors:osteosarcomaandrelatedtumors.CancerGenetCytogenet.2003;145:1–30.211.SangiorgiL,GobbiGA,LucarelliE,SartorioSM,MordentiM,GhediniI,MainiV,ScrimieriF,ReggianiM,BertojaAZ,BenassiMS,PicciP.Presenceoftelomeraseactivityindifferentmusculoskeletaltumorhistotypesandcorrelationwithaggres-siveness.IntJCancer.202001;95:156–161.212.ScheelC,SchaeferKL,JauchA,KellerM,WaiD,BrinkschmidtC,vanValenF,BoeckerW,Dockhorn-DworniczakB,PorembaC.Alternativelengtheningoftelomeresisassociatedwithchro-mosomalinstabilityinosteosarcomas.Oncogene.2001;20:3835–3844.213.SchmidtEE,IchimuraK,ReifenbergerG,CollinsVP.CDKN2(p16/MTS1)genedeletionorCDK4ampliﬁcationoccursinthemajorityofglioblastomas.CancerRes.1994;54:6321–6324.214.Schneider-StockR,RadigK,OdaY,MellinW,RysJ,NiezabitowskiA,RoessnerA.p53genemutationsinsoft-tissuesarcomas–correlationswithp53immunohistochemistryandDNAploidy.JCancerResClinOncol.1997;123:211–218.215.ScholzRB,KabischH,WeberB,RoserK,DellingG,WinklerK.StudiesoftheRB1geneandthep53geneinhumanosteo-sarcomas.PediatrHematolOncol.1992;9:125–137.216.ScotlandiK,BaldiniN,OlivieroM,DiRenzoMF,MartanoM,SerraM,ManaraMC,ComoglioPM,FerraciniR.ExpressionofMet/hepatocytegrowthfactorreceptorgeneandmalignant2128Tangetal.ClinicalOrthopaedicsandRelatedResearch123behaviorofmusculoskeletaltumors.AmJPathol.1996;149:1209–1219.217.SellS.Stemcelloriginofcanceranddifferentiationtherapy.CritRevOncolHematol.2004;51:1–28.218.ShiratoriH,KoshinoT,UesugiM,NittoH,SaitoT.Accelera-tionoflungmetastasisbyup-regulationofCD44expressioninosteosarcoma-derivedcelltransplantedmice.CancerLett.2001;170:177–182.219.SiggelkowH,SchenckM,RohdeM,ViereckV,TauberS,AtkinsonMJ,HufnerM.ProlongedcultureofHOS58humanosteosarcomacellswith1,25-(OH)2-D3,TGF-beta,anddexa-methasonerevealsphysiologicalregulationofalkalinephosphatase,dissociatedosteocalcingeneexpression,andpro-teinsynthesisandlackofmineralization.JCellBiochem.2002;85:279–294.220.SimonsA,SchepensM,ForusA,GodagerL,vanAsseldonkM,MyklebostO,vanKesselAG.Anovelchromosomalregionofallelicloss,4q32-q34,inhumanosteosarcomasrevealedbyrepresentationaldifferenceanalysis.GenesChromosomesCan-cer.1999;26:115–124.221.Smith-SorensenB,GebhardtMC,KloenP,McIntyreJ,AguilarF,CeruttiP,BorresenAL.ScreeningforTP53mutationsinosteosarcomasusingconstantdenaturantgelelectrophoresis(CDGE).HumMutat.1993;2:274–285.222.SparksAB,PetersonSN,BellC,LoftusBJ,HockingL,CahillDP,FrassicaFJ,StreetenEA,LevineMA,FraserCM,AdamsMD,BroderS,VenterJC,KinzlerKW,VogelsteinB,RalstonSH.MutationscreeningoftheTNFRSF11AgeneencodingreceptoractivatorofNFkappaB(RANK)infamilialandspo-radicPaget’sdiseaseofboneandosteosarcoma.CalcifTissueInt.2001;68:151–155.223.SrivastavaS,ZouZQ,PirolloK,BlattnerW,ChangEH.Germ-linetransmissionofamutatedp53geneinacancer-pronefamilywithLi-Fraumenisyndrome.Nature.1990;348:747–749.224.SteinU,EderC,KarstenU,HaenschW,WaltherW,SchlagPM.GLIgeneexpressioninboneandsofttissuesarcomasofadultpatientscorrelateswithtumorgrade.CancerRes.1999;59:1890–1895.225.SuYA,HutterCM,TrentJM,MeltzerPS.Completesequenceanalysisofagene(OS-9)ubiquitouslyexpressedinhumantis-suesandampliﬁedinsarcomas.MolCarcinog.1996;15:270–275.226.SuYA,LeeMM,HutterCM,MeltzerPS.Characterizationofahighlyconservedgene(OS4)ampliﬁedwithCDK4inhumansarcomas.Oncogene.1997;15:1289–1294.227.SztanM,PapaiZ,SzendroiM,LooijM,OlahE.Alleliclossesfromchromosome17inhumanosteosarcomas.PatholOncolRes.1997;3:115–120.228.TaichmanRS,CooperC,KellerET,PientaKJ,TaichmanNS,McCauleyLK.Useofthestromalcell-derivedfactor-1/CXCR4pathwayinprostatecancermetastasistobone.CancerRes.2002;62:1832–1837.229.TakedaS,ElefteriouF,KarsentyG.Commonendocrinecontrolofbodyweight,reproduction,andbonemass.AnnuRevNutr.2003;23:403–411.230.TakedaS,KarsentyG.Centralcontrolofboneformation.JBoneMinerMetab.2001;19:195–198.231.ThomasD,KansaraM.Epigeneticmodiﬁcationsinosteogenicdifferentiationandtransformation.JCellBiochem.2006;98:757–769.232.ThomasDM,CartySA,PiscopoDM,LeeJS,WangWF,ForresterWC,HindsPW.Theretinoblastomaproteinactsasatranscriptionalcoactivatorrequiredforosteogenicdifferentia-tion.MolCell.2001;8:303–316.233.ThomasDM,JohnsonSA,SimsNA,TrivettMK,SlavinJL,RubinBP,WaringP,McArthurGA,WalkleyCR,HollowayAJ,DiyagamaD,GrimJE,ClurmanBE,BowtellDD,LeeJS,GutierrezGM,PiscopoDM,CartySA,HindsPW.Terminalosteoblastdifferentiation,mediatedbyrunx2andp27KIP1,isdisruptedinosteosarcoma.JCellBiol.2004;167:925–934.234.TirodeF,Laud-DuvalK,PrieurA,DelormeB,CharbordP,DelattreO.MesenchymalstemcellfeaturesofEwingtumors.CancerCell.2007;11:421–429.235.ToguchidaJ,IshizakiK,SasakiMS,IkenagaM,SugimotoM,KotouraY,YamamuroT.Chromosomalreorganizationfortheexpressionofrecessivemutationofretinoblastomasusceptibilitygeneinthedevelopmentofosteosarcoma.CancerRes.1988;48:3939–3943.236.ToguchidaJ,YamaguchiT,DaytonSH,BeauchampRL,HerreraGE,IshizakiK,YamamuroT,MeyersPA,LittleJB,SasakiMS,etal.Prevalenceandspectrumofgermlinemuta-tionsofthep53geneamongpatientswithsarcoma.NEnglJMed.1992;326:1301–1308.237.ToguchidaJ,YamaguchiT,RitchieB,BeauchampRL,DaytonSH,HerreraGE,YamamuroT,KotouraY,SasakiMS,LittleJB,etal.Mutationspectrumofthep53geneinboneandsofttissuesarcomas.CancerRes.1992;52:6194–6199.238.TorchiaEC,JaishankarS,BakerSJ.Ewingtumorfusionpro-teinsblockthedifferentiationofpluripotentmarrowstromalcells.CancerRes.2003;63:3464–3468.239.TuckerMA,D’AngioGJ,BoiceJDJr,StrongLC,LiFP,StovallM,StoneBJ,GreenDM,LombardiF,NewtonW,etal.Bonesarcomaslinkedtoradiotherapyandchemotherapyinchildren.NEnglJMed.1987;317:588–593.240.UchiboriM,NishidaY,NagasakaT,YamadaY,NakanishiK,IshiguroN.Increasedexpressionofmembrane-typematrixmetalloproteinase-1iscorrelatedwithpoorprognosisinpatientswithosteosarcoma.IntJOncol.2006;28:33–42.241.UedaY,Dockhorn-DworniczakB,BlasiusS,MellinW,WuismanP,BockerW,RoessnerA.AnalysisofmutantP53proteininosteosarcomasandothermalignantandbenignlesionsofbone.JCancerResClinOncol.1993;119:172–178.242.UlanerGA,HuangHY,OteroJ,ZhaoZ,Ben-PoratL,Satago-panJM,GorlickR,MeyersP,HealeyJH,HuvosAG,HoffmanAR,LadanyiM.Absenceofatelomeremaintenancemechanismasafavorableprognosticfactorinpatientswithosteosarcoma.CancerRes.2003;63:1759–1763.243.vanDartelM,CornelissenPW,RedekerS,TarkkanenM,KnuutilaS,HogendoornPC,WesterveldA,GomesI,BrasJ,HulsebosTJ.Ampliﬁcationof17p11.2approximatelyp12,includingPMP22,TOP3A,andMAPK7,inhigh-gradeosteo-sarcoma.CancerGenetCytogenet.2002;139:91–96.244.vanDartelM,HulsebosTJ.CharacterizationofPMP22expressioninosteosarcoma.CancerGenetCytogenet.2004;152:113–118.245.vanDeursenJM.Rblosscausescancerbydrivingmitosismad.CancerCell.2007;11:1–3.246.vanEsJH,BarkerN,CleversH.YouWntsome,youlosesome:oncogenesintheWntsignalingpathway.CurrOpinGenetDev.2003;13:28–33.247.VogelsteinB,LaneD,LevineAJ.Surﬁngthep53network.Nature.2000;408:307–310.248.WadayamaB,ToguchidaJ,ShimizuT,IshizakiK,SasakiMS,KotouraY,YamamuroT.Mutationspectrumoftheretino-blastomageneinosteosarcomas.CancerRes.1994;54:3042–3048.249.WadayamaB,ToguchidaJ,YamaguchiT,SasakiMS,YamamuroT.p53expressionanditsrelationshiptoDNAalterationsinboneandsofttissuesarcomas.BrJCancer.1993;68:1134–1139.250.WagnerEF,KarsentyG.Geneticcontrolofskeletaldevelop-ment.CurrOpinGenetDev.2001;11:527–532.Volume466,Number9,September2008MolecularPathogenesisofOsteosarcoma2129123251.WanX,MendozaA,KhannaC,HelmanLJ.Rapamycininhibitsezrin-mediatedmetastaticbehaviorinamurinemodelofoste-osarcoma.CancerRes.2005;65:2406–2411.252.WangLL.Biologyofosteogenicsarcoma.CancerJ.2005;11:294–305.253.WangLL,GannavarapuA,KozinetzCA,LevyML,LewisRA,ChintagumpalaMM,Ruiz-MaldanadoR,Contreras-RuizJ,CunniffC,EricksonRP,LevD,RogersM,ZackaiEH,PlonSE.AssociationbetweenosteosarcomaanddeleteriousmutationsintheRECQL4geneinRothmund-Thomsonsyndrome.JNatlCancerInst.2003;95:669–674.254.WangLL,LevyML,LewisRA,ChintagumpalaMM,LevD,RogersM,PlonSE.Clinicalmanifestationsinacohortof41Rothmund-Thomsonsyndromepatients.AmJMedGenet.2001;102:11–17.255.WangZQ,LiangJ,SchellanderK,WagnerEF,GrigoriadisAE.c-fos-inducedosteosarcomaformationintransgenicmice:cooperativitywithc-junandtheroleofendogenousc-fos.CancerRes.1995;55:6244–6251.256.WeatherbyRP,DahlinDC,IvinsJC.Postradiationsarcomaofbone:reviewof78MayoCliniccases.MayoClinProc.1981;56:294–306.257.WeiG,LonardoF,UedaT,KimT,HuvosAG,HealeyJH,LadanyiM.CDK4geneampliﬁcationinosteosarcoma:reci-procalrelationshipwithINK4Agenealterationsandmappingof12q13amplicons.IntJCancer.1999;80:199–204.258.WeissKR,CooperGM,JadlowiecJA,McGoughRL3rd,HuardJ.VEGFandBMPexpressioninmouseosteosarcomacells.ClinOrthopRelatRes.2006;450:111–117.259.WhelanJS.Osteosarcoma.EurJCancer.1997;33:1611–1618;discussion1618–1619.260.WichaMS,LiuS,DontuG.Cancerstemcells:anoldidea—aparadigmshift.CancerRes.2006;66:1883–1890;discussion1895–1886.261.WilkieAO,PateySJ,KanSH,vandenOuwelandAM,HamelBC.FGFs,theirreceptors,andhumanlimbmalformations:clinicalandmolecularcorrelations.AmJMedGenet.2002;112:266–278.262.WillertK,NusseR.Beta-catenin:akeymediatorofWntsig-naling.CurrOpinGenetDev.1998;8:95–102.263.WinslowMM,PanM,StarbuckM,GalloEM,DengL,KarsentyG,CrabtreeGR.Calcineurin/NFATsignalinginosteoblastsregulatesbonemass.DevCell.2006;10:771–782.264.WodarzA,NusseR.MechanismsofWntsignalingindevel-opment.AnnuRevCellDevBiol.1998;14:59–88.265.WolfM,El-RifaiW,TarkkanenM,KononenJ,SerraM,EriksenEF,ElomaaI,KallioniemiA,KallioniemiOP,KnuutilaS.Novelﬁndingsingeneexpressiondetectedinhumanosteo-sarcomabycDNAmicroarray.CancerGenetCytogenet.2000;123:128–132.266.WuJX,CarpenterPM,GresensC,KehR,NimanH,MorrisJW,MercolaD.Theproto-oncogenec-fosisover-expressedinthemajorityofhumanosteosarcomas.Oncogene.1990;5:989–1000.267.WunderJS,CzitromAA,KandelR,AndrulisIL.Analysisofalterationsintheretinoblastomageneandtumorgradeinboneandsoft-tissuesarcomas.JNatlCancerInst.1991;83:194–200.268.WunderJS,EppertK,BurrowSR,GokgozN,BellRS,AndrulisIL.Co-ampliﬁcationandoverexpressionofCDK4,SASandMDM2occursfrequentlyinhumanparostealosteosarcomas.Oncogene.1999;18:783–788.269.WuytsW,VanWesenbeeckL,Morales-PigaA,RalstonS,HockingL,VanhoenackerF,WesthovensR,VerbruggenL,AndersonD,HughesA,VanHulW.EvaluationoftheroleofRANKandOPGgenesinPaget’sdiseaseofbone.Bone.2001;28:104–107.270.YamaguchiA,KomoriT,SudaT.Regulationofosteoblastdifferentiationmediatedbybonemorphogeneticproteins,hedgehogs,andCbfa1.EndocrRev.2000;21:393–411.271.YamaguchiT,ToguchidaJ,YamamuroT,KotouraY,TakadaN,KawaguchiN,KanekoY,NakamuraY,SasakiMS,IshizakiK.Allelotypeanalysisinosteosarcomas:frequentallelelosson3q,13q,17p,and18q.CancerRes.1992;52:2419–2423.272.YanP,CoindreJM,BenhattarJ,BosmanFT,GuillouL.Telo-meraseactivityandhumantelomerasereversetranscriptasemRNAexpressioninsofttissuetumors:correlationwithgrade,histology,andproliferativeactivity.CancerRes.1999;59:3166–3170.273.YangX,KarsentyG.ATF4,theosteoblastaccumulationofwhichisdeterminedpost-translationally,caninduceosteoblast-speciﬁcgeneexpressioninnon-osteoblasticcells.JBiolChem.2004;279:47109–47114.274.YokoyamaR,Schneider-StockR,RadigK,WexT,RoessnerA.ClinicopathologicimplicationsofMDM2,p53andK-rasgenealterationsinosteosarcomas:MDM2ampliﬁcationandp53mutationsfoundinprogressivetumors.PatholResPract.1998;194:615–621.275.YoshikawaH,NakaseT,MyouiA,UedaT.Bonemorphoge-neticproteinsinbonetumors.JOrthopSci.2004;9:334–340.276.YotovWV,HamelH,RivardGE,ChampagneMA,RussoPA,LeclercJM,BernsteinML,LevyE.AmpliﬁcationsofDNAprimase1(PRIM1)inhumanosteosarcoma.GenesChromo-somesCancer.1999;26:62–69.277.ZenmyoM,KomiyaS,HamadaT,HiraokaK,KatoS,FujiiT,YanoH,IrieK,NagataK.Transcriptionalactivationofp21byvitaminD(3)orvitaminK(2)leadstodifferentiationofp53-deﬁcientMG-63osteosarcomacells.HumPathol.2001;32:410–416.278.ZhangM,RosenJM.Stemcellsintheetiologyandtreatmentofcancer.CurrOpinGenetDev.2006;16:60–64.279.ZhangY,XiongY,YarbroughWG.ARFpromotesMDM2degradationandstabilizesp53:ARF-INK4alocusdeletionimpairsboththeRbandp53tumorsuppressionpathways.Cell.1998;92:725–734.280.ZhaoGQ.ConsequencesofknockingoutBMPsignalinginthemouse.Genesis.2003;35:43–56.281.ZhouH,RandallRL,BrothmanAR,MaxwellT,CofﬁnCM,GoldsbyRE.Her-2/neuexpressioninosteosarcomaincreasesriskoflungmetastasisandcanbeassociatedwithgeneampli-ﬁcation.JPediatrHematolOncol.2003;25:27–32.282.ZouH,ChoeKM,LuY,MassagueJ,NiswanderL.BMPsig-nalingandvertebratelimbdevelopment.ColdSpringHarbSympQuantBiol.1997;62:269–272.2130Tangetal.ClinicalOrthopaedicsandRelatedResearch123